https://m2.mtmt.hu/ hun 2026-09-20 21:09 JournalArticle 31991804 VALIDATED true Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of SciencesBratislava 84104, Slovakia Institute of Physiology, Faculty of Medicine, Comenius University in BratislavaBratislava 81372, Slovakia Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in BratislavaBratislava 83232, Slovakia Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, 1085, Hungary Pharmahungary Group, Szeged, 6722, Hungary Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of SciencesBratislava 81371, Slovakia Laboratory of Animal Physiology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, And Department of Physiology & Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0W2, Canada Cited By :57 Export Date: 4 September 2024 CODEN: FRBME Correspondence Address: Barteková, M.; Institute for Heart Research, Slovakia; email: monika.bartekova@savba.sk Correspondence Address: Giricz, Z.; Department of Pharmacology and Pharmacotherapy, Hungary 0 false 2026-08-10T20:25:01.953+0000 2024-09-17T07:53:19.630+0000 2021-04-28T18:05:34.428+0000 true 10010125 Ferdinandy Péter /api/author/10010125 Author Ferdinandy Péter (Farmakológia, molekuláris medicina) true 10010125 2026-07-16T09:09:44.455+0000 2024-09-01T21:01:41.654+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 Admin 10073918 /api/admin/10073918 Kovács Marcell (MTMT Közp., admin) Kovács Marcell true true 2024-09-09T07:21:55.189+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Barteková, Monika true true /api/journal/1638 REVIEWED FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 1873-4596 true false 1638 false 1638 true 0891-5849 1873-4596 Journal FOREIGN 169 446 477 446 32 2021 Funding 2009255 /api/funding/2009255 (NVKP_16-1-20160017) Támogató: Hungarian National Research, Development and Innovation Office false true Funding 2009256 /api/funding/2009256 (Higher Education Institutional Excellence Programme of the Ministry of Human Capacities of Hungary, within the framework of the Therapeutic Development thematic programme of the Semmelweis University) false true Funding 2009257 /api/funding/2009257 (TKP/ITM/NKFIH) false true Funding 2009258 /api/funding/2009258 (ÚNKP-19-4) false true true true 2021 true true true false true false GOLD 2026-08-10 true https://doi.org/10.1016/j.freeradbiomed.2021.03.045 99 0 98 81 0 98 93 78 94 95 95 78 78 82 17 0 99 82 98 81 0 20 20 Folyóiratcikk Journal Article 24 92 Könyvrészlet Chapter in Book 25 6 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 1 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2021 0 14 10 14 10 2022 0 13 10 13 10 2023 0 23 22 23 22 2024 0 17 12 17 12 2025 0 24 20 24 20 2026 0 8 8 8 8 Q1 false 10027602,10026898 false false false 2021-05-10T20:06:20.304+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 3 20 1 9 0 true 10073918 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 96141099 /api/authorship/96141099 Barteková, Monika ✉ 1 0.111 true false true Barteková Monika true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141100 /api/authorship/96141100 Adameová, Adriana 2 0.11111111 false false false Adameová Adriana true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141101 /api/authorship/96141101 Görbe, Anikó [Görbe, Anikó (orvostudomany), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 3 0.111 false false false Author 10027602 /api/author/10027602 Görbe Anikó (orvostudomany) Görbe Anikó true 10027602 true Görbe Anikó true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141102 /api/authorship/96141102 Ferenczyová, Kristína 4 0.11111111 false false false Ferenczyová Kristína true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141103 /api/authorship/96141103 Pecháňová, Oľga 5 0.11111111 false false false Pecháňová Oľga true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141104 /api/authorship/96141104 Lazou, Antigone 6 0.11111111 false false false Lazou Antigone true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141105 /api/authorship/96141105 Dhalla, Naranjan S. 7 0.11111111 false false false Dhalla Naranjan S. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141106 /api/authorship/96141106 Ferdinandy, Péter [Ferdinandy, Péter (Farmakológia, mol...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 8 0.111 false false false Author 10010125 /api/author/10010125 Ferdinandy Péter (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96141107 /api/authorship/96141107 Giricz, Zoltán ✉ [Giricz, Zoltán (Biokémia, Farmako...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 9 0.111 false true true Author 10026898 /api/author/10026898 Giricz Zoltán (Biokémia, Farmakológia) Giricz Zoltán true 10026898 true Giricz Zoltán true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18725208 /api/publicationidentifier/18725208 DOI: 10.1016/j.freeradbiomed.2021.03.045 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.freeradbiomed.2021.03.045 https://doi.org/10.1016/j.freeradbiomed.2021.03.045 false true PublicationIdentifier 18929584 /api/publicationidentifier/18929584 WoS: 000653022000003 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000653022000003 https://www.webofscience.com/wos/woscc/full-record/000653022000003 false true PublicationIdentifier 18799513 /api/publicationidentifier/18799513 Scopus: 85105314704 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85105314704 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85105314704 false true PublicationIdentifier 18725231 /api/publicationidentifier/18725231 PubMed: 33905865 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 33905865 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33905865&dopt=Abstract true true Classification 10575 /api/classification/10575 Biokémia és molekuláris biológia true true Classification 12283 /api/classification/12283 Endokrinológia és anyagcserebetegségek (benne cukorbetegség, hormonok) true true SjrRating 11196144 /api/sjrrating/11196144 sjr:Q1 (2021) Scopus - Biochemistry FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 1873-4596 64 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1303 /api/classificationexternal/1303 Scopus - Biochemistry true 1303 true Q1 DIRECT true true Reference 20129052 /api/reference/20129052 1. Pescatello 1999: Physical Activity, Cardiometabolic Health and Older Adults, Sport. Med., 28, p. 315, DOI: 10.2165/00007256-199928050-00003 1 10.2165/00007256-199928050-00003 false true Reference 20129053 /api/reference/20129053 2. WHO 2017, https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1, (n.d.). 2 false true Reference 20129054 /api/reference/20129054 3. Borghetti 2018: Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control, Front. Physiol., 9, DOI: 10.3389/fphys.2018.01514 3 10.3389/fphys.2018.01514 false true Reference 20129055 /api/reference/20129055 4. Jia 2018: Diabetic Cardiomyopathy, Circ. Res., 122, p. 624, DOI: 10.1161/CIRCRESAHA.117.311586 4 10.1161/CIRCRESAHA.117.311586 false true Reference 20129056 /api/reference/20129056 5. Lontchi-Yimagou 2013: Diabetes Mellitus and Inflammation, Curr. Diab. Rep., 13, p. 435, DOI: 10.1007/s11892-013-0375-y 5 10.1007/s11892-013-0375-y false true Reference 20129057 /api/reference/20129057 6. Mirtschink 2018: Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease, Eur. Heart J., 39, p. 2497, DOI: 10.1093/eurheartj/ehx518 6 10.1093/eurheartj/ehx518 false true Reference 20129058 /api/reference/20129058 7. Hui 2016: Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease, Curr. Opin. Lipidol., 27, p. 507, DOI: 10.1097/MOL.0000000000000334 7 10.1097/MOL.0000000000000334 false true Reference 20129059 /api/reference/20129059 8. Scheja 2019: The endocrine function of adipose tissues in health and cardiometabolic disease, Nat. Rev. Endocrinol., 15, p. 507, DOI: 10.1038/s41574-019-0230-6 8 10.1038/s41574-019-0230-6 false true Reference 20129060 /api/reference/20129060 9. Lawson 2016: Microvesicles and exosomes: new players in metabolic and cardiovascular disease, J. Endocrinol., 228, p. R57, DOI: 10.1530/JOE-15-0201 9 10.1530/JOE-15-0201 false true Reference 20129061 /api/reference/20129061 10. Craige 2019: JNK and cardiometabolic dysfunction, Biosci. Rep., 39, DOI: 10.1042/BSR20190267 10 10.1042/BSR20190267 false true Reference 20129062 /api/reference/20129062 11. Daiber 2017: Pharmacology of oxidative stress: translational opportunities, Br. J. Pharmacol., 174, p. 1511, DOI: 10.1111/bph.13795 11 10.1111/bph.13795 false true Reference 20129063 /api/reference/20129063 12. Cicero 2017: Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach, Food Funct, 8, p. 2076, DOI: 10.1039/C7FO00178A 12 10.1039/C7FO00178A false true Reference 20129064 /api/reference/20129064 13. Andreadou 2017: Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning, Br. J. Pharmacol., 174, p. 1555, DOI: 10.1111/bph.13704 13 10.1111/bph.13704 false true Reference 20129065 /api/reference/20129065 14. Ferdinandy 2014: Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning, Pharmacol. Rev., 66, p. 1142, DOI: 10.1124/pr.113.008300 14 10.1124/pr.113.008300 false true Reference 20129066 /api/reference/20129066 15. Csonka 2016: Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart, Oxid. Med. Cell. Longev., p. 1, DOI: 10.1155/2016/3863726 15 10.1155/2016/3863726 false true Reference 20129067 /api/reference/20129067 16. Varga 2013: MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart, J. Mol. Cell. Cardiol., 62, p. 111, DOI: 10.1016/j.yjmcc.2013.05.009 16 10.1016/j.yjmcc.2013.05.009 false true Reference 20129068 /api/reference/20129068 17. Itoh 2002: Importance of NAD(P)H Oxidase–Mediated Oxidative Stress and Contractile Type Smooth Muscle Myosin Heavy Chain SM2 at the Early Stage of Atherosclerosis, Circulation, 105, p. 2288, DOI: 10.1161/01.CIR.0000015607.33345.1F 17 10.1161/01.CIR.0000015607.33345.1F false true Reference 20129069 /api/reference/20129069 18. Kontush 1997: Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia, Atherosclerosis, 129, p. 119, DOI: 10.1016/S0021-9150(96)06021-2 18 10.1016/S0021-9150(96)06021-2 false true Reference 20129070 /api/reference/20129070 19. Sharma 2016: Coenzyme Q10 and Heart Failure, Circ. Hear. Fail., 9 19 false true Reference 20129071 /api/reference/20129071 20. Ruotsalainen 2019: Nuclear factor E2-related factor 2 deficiency impairs atherosclerotic lesion development but promotes features of plaque instability in hypercholesterolaemic mice, Cardiovasc. Res., 115, p. 243, DOI: 10.1093/cvr/cvy143 20 10.1093/cvr/cvy143 false true Reference 20129072 /api/reference/20129072 21. Kertész 2013: Adverse Impact of Diet-Induced Hypercholesterolemia on Cardiovascular Tissue Homeostasis in a Rabbit Model: Time-Dependent Changes in Cardiac Parameters, Int. J. Mol. Sci., 14, p. 19086, DOI: 10.3390/ijms140919086 21 10.3390/ijms140919086 false true Reference 20129073 /api/reference/20129073 22. Andreadou 2021: Influence of cardiometabolic comorbidities on myocardial function, infarction, and CARDIOPROTECTION: Role of cardiac redox signaling, Free Radic. Biol. Med., DOI: 10.1016/j.freeradbiomed.2021.02.012 22 10.1016/j.freeradbiomed.2021.02.012 false true Reference 20129074 /api/reference/20129074 23. Rajesh 2010: Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy, J. Am. Coll. Cardiol., 56, p. 2115, DOI: 10.1016/j.jacc.2010.07.033 23 10.1016/j.jacc.2010.07.033 false true Reference 20129075 /api/reference/20129075 24. Rezende 2018: The NADPH organizers NoxO1 and p47phox are both mediators of diabetes-induced vascular dysfunction in mice, Redox Biol, 15, p. 12, DOI: 10.1016/j.redox.2017.11.014 24 10.1016/j.redox.2017.11.014 false true Reference 20129076 /api/reference/20129076 25. Rajesh 2009: Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy, J. Cell. Mol. Med., 13, p. 2330, DOI: 10.1111/j.1582-4934.2008.00564.x 25 10.1111/j.1582-4934.2008.00564.x false true Reference 20129077 /api/reference/20129077 26. Jo 2011: Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin-induced diabetic mice, Clin. Exp. Pharmacol. Physiol., 38, p. 485, DOI: 10.1111/j.1440-1681.2011.05535.x 26 10.1111/j.1440-1681.2011.05535.x false true Reference 20129078 /api/reference/20129078 27. Faria 2017: Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential, Pharmacol. Ther., 172, p. 50, DOI: 10.1016/j.pharmthera.2016.11.013 27 10.1016/j.pharmthera.2016.11.013 false true Reference 20129079 /api/reference/20129079 28. Nowotny 2015: Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus, Biomolecules, 5, p. 194, DOI: 10.3390/biom5010194 28 10.3390/biom5010194 false true Reference 20129080 /api/reference/20129080 29. Deshwal 2018: Monoamine oxidase-dependent endoplasmic reticulum-mitochondria dysfunction and mast cell degranulation lead to adverse cardiac remodeling in diabetes, Cell Death Differ, 25, p. 1671, DOI: 10.1038/s41418-018-0071-1 29 10.1038/s41418-018-0071-1 false true Reference 20129081 /api/reference/20129081 30. Kaludercic 2020: Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy, Front. Cardiovasc. Med., 7, DOI: 10.3389/fcvm.2020.00012 30 10.3389/fcvm.2020.00012 false true Reference 20129082 /api/reference/20129082 31. Koncsos 2016: Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress, Am. J. Physiol. Circ. Physiol., 311, p. H927, DOI: 10.1152/ajpheart.00049.2016 31 10.1152/ajpheart.00049.2016 false true Reference 20129083 /api/reference/20129083 32. Fancher 2013: Diabetes mellitus reduces the function and expression of ATP-dependent K+ channels in cardiac mitochondria, Life Sci, 92, p. 664, DOI: 10.1016/j.lfs.2012.11.019 32 10.1016/j.lfs.2012.11.019 false true Reference 20129084 /api/reference/20129084 33. Adameova 2020: Role of Oxidative Stress in the Genesis of Ventricular Arrhythmias, Int. J. Mol. Sci., 21, p. 4200, DOI: 10.3390/ijms21124200 33 10.3390/ijms21124200 false true Reference 20129085 /api/reference/20129085 34. Dhalla 2019: Role of catecholamines in the pathogenesis of diabetic cardiomyopathy, Can. J. Physiol. Pharmacol., 97, p. 815, DOI: 10.1139/cjpp-2019-0044 34 10.1139/cjpp-2019-0044 false true Reference 20129086 /api/reference/20129086 35. Ates 2013: Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy, Int. J. Ophthalmol., 6, p. 675 35 false true Reference 20129087 /api/reference/20129087 36. Ye 2004: Catalase Protects Cardiomyocyte Function in Models of Type 1 and Type 2 Diabetes, Diabetes, 53, p. 1336, DOI: 10.2337/diabetes.53.5.1336 36 10.2337/diabetes.53.5.1336 false true Reference 20129088 /api/reference/20129088 37. Wang 2009: Inactivation of GSK-3 by Metallothionein Prevents Diabetes-Related Changes in Cardiac Energy Metabolism, Inflammation, Nitrosative Damage, and Remodeling, Diabetes, 58, p. 1391, DOI: 10.2337/db08-1697 37 10.2337/db08-1697 false true Reference 20129089 /api/reference/20129089 38. He 2009: Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes, J. Mol. Cell. Cardiol., 46, p. 47, DOI: 10.1016/j.yjmcc.2008.10.007 38 10.1016/j.yjmcc.2008.10.007 false true Reference 20129090 /api/reference/20129090 39. Tan 2011: Diabetic Downregulation of Nrf2 Activity via ERK Contributes to Oxidative Stress-Induced Insulin Resistance in Cardiac Cells In Vitro and In Vivo, Diabetes, 60, p. 625, DOI: 10.2337/db10-1164 39 10.2337/db10-1164 false true Reference 20129091 /api/reference/20129091 40. Bergamini 2009: Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure, Eur. J. Heart Fail., 11, p. 444, DOI: 10.1093/eurjhf/hfp042 40 10.1093/eurjhf/hfp042 false true Reference 20129092 /api/reference/20129092 41. P. Son, L. Lewis, Hyperhomocysteinemia, 2020. http://www.ncbi.nlm.nih.gov/pubmed/32119295. 41 false true Reference 20129093 /api/reference/20129093 42. Kietadisorn 2011: Role of tetrahydrobiopterin (BH4) in hyperhomocysteinemia-induced endothelial dysfuction: new indication for this orphan-drug?, Am. J. Physiol. Metab., 300 42 false true Reference 20129094 /api/reference/20129094 43. Koller 2018: Coronary Microvascular and Cardiac Dysfunction Due to Homocysteine Pathometabolism; A Complex Therapeutic Design, Curr. Pharm. Des., 24, p. 2911, DOI: 10.2174/1381612824666180625125450 43 10.2174/1381612824666180625125450 false true Reference 20129095 /api/reference/20129095 44. Derouiche 2014: Hyperhomocysteinemia-induced oxidative stress differentially alters proteasome composition and activities in heart and aorta, Biochem. Biophys. Res. Commun., 452, p. 740, DOI: 10.1016/j.bbrc.2014.08.141 44 10.1016/j.bbrc.2014.08.141 false true Reference 20129096 /api/reference/20129096 45. Adameova 2009: Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease, Can. J. Physiol. Pharmacol., 87, p. 493, DOI: 10.1139/Y09-042 45 10.1139/Y09-042 false true Reference 20129097 /api/reference/20129097 46. Dhalla 2000: Role of oxidative stress in cardiovascular diseases, J. Hypertens., 18, p. 655, DOI: 10.1097/00004872-200018060-00002 46 10.1097/00004872-200018060-00002 false true Reference 20129098 /api/reference/20129098 47. Rosa 2013: Diabetes mellitus activates fetal gene program and intensifies cardiac remodeling and oxidative stress in aged spontaneously hypertensive rats, Cardiovasc. Diabetol., 12, p. 152, DOI: 10.1186/1475-2840-12-152 47 10.1186/1475-2840-12-152 false true Reference 20129099 /api/reference/20129099 48. Monji 2013: Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes, Am. J. Physiol. Circ. Physiol., 305, p. H295, DOI: 10.1152/ajpheart.00990.2012 48 10.1152/ajpheart.00990.2012 false true Reference 20129100 /api/reference/20129100 49. Guido 2017: The Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative Stress, Inflammatory Cells, and Fibrosis between Subendocardial and Interstitial Myocardial Areas, Oxid. Med. Cell. Longev., p. 1, DOI: 10.1155/2017/5343972 49 10.1155/2017/5343972 false true Reference 20129101 /api/reference/20129101 50. Adameova 2014: Role of microangiopathy in diabetic cardiomyopathy, Heart Fail, Rev, 19, p. 25 50 false true Reference 20129102 /api/reference/20129102 51. Neuman 2007: Oxidative Stress Markers Are Associated with Persistent Atrial Fibrillation, Clin. Chem., 53, p. 1652, DOI: 10.1373/clinchem.2006.083923 51 10.1373/clinchem.2006.083923 false true Reference 20129103 /api/reference/20129103 52. Goldhaber 1992: Oxygen free radicals and cardiac reperfusion abnormalities, Hypertension, 20, p. 118, DOI: 10.1161/01.HYP.20.1.118 52 10.1161/01.HYP.20.1.118 false true Reference 20129104 /api/reference/20129104 53. Kuehls 1980: Inflammation: the role of peroxidase-derived products, Adv Prostaglandin Thromboxane Res, 6, p. 77 53 false true Reference 20129105 /api/reference/20129105 54. Zorov 2000: Reactive Oxygen Species (Ros-Induced) Ros Release, J. Exp. Med., 192, p. 1001, DOI: 10.1084/jem.192.7.1001 54 10.1084/jem.192.7.1001 false true Reference 20129106 /api/reference/20129106 55. Cardoso 2003: Prognostic value of QT interval parameters in type 2 diabetes mellitus, J. Diabetes Complications., 17, p. 169, DOI: 10.1016/S1056-8727(02)00206-4 55 10.1016/S1056-8727(02)00206-4 false true Reference 20129107 /api/reference/20129107 56. Homan 2019: Clinical Overview of Obesity and Diabetes Mellitus as Risk Factors for Atrial Fibrillation and Sudden Cardiac Death, Front. Physiol., 9, DOI: 10.3389/fphys.2018.01847 56 10.3389/fphys.2018.01847 false true Reference 20129108 /api/reference/20129108 57. Kim 2005: A Myocardial Nox2 Containing NAD(P)H Oxidase Contributes to Oxidative Stress in Human Atrial Fibrillation, Circ. Res., 97, p. 629, DOI: 10.1161/01.RES.0000183735.09871.61 57 10.1161/01.RES.0000183735.09871.61 false true Reference 20129109 /api/reference/20129109 58. Zhang 2012: NOX4-Dependent Hydrogen Peroxide Overproduction in Human Atrial Fibrillation and HL-1 Atrial Cells: Relationship to Hypertension, Front. Physiol., 3, DOI: 10.3389/fphys.2012.00140 58 10.3389/fphys.2012.00140 false true Reference 20129110 /api/reference/20129110 59. Benjamin 1994: Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort, JAMA, 271, p. 840, DOI: 10.1001/jama.1994.03510350050036 59 10.1001/jama.1994.03510350050036 false true Reference 20129111 /api/reference/20129111 60. Aune 2018: Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies, J. Diabetes Complications., 32, p. 501, DOI: 10.1016/j.jdiacomp.2018.02.004 60 10.1016/j.jdiacomp.2018.02.004 false true Reference 20129112 /api/reference/20129112 61. Baek 2017: Associations of Abdominal Obesity and New‐Onset Atrial Fibrillation in the General Population, J. Am. Heart Assoc., 6, DOI: 10.1161/JAHA.116.004705 61 10.1161/JAHA.116.004705 false true Reference 20129113 /api/reference/20129113 62. Maharani 2016: Hyperuricemia and Atrial Fibrillation, Int. Heart J., 57, p. 395, DOI: 10.1536/ihj.16-192 62 10.1536/ihj.16-192 false true Reference 20129114 /api/reference/20129114 63. Mihm 2001: Impaired Myofibrillar Energetics and Oxidative Injury During Human Atrial Fibrillation, Circulation, 104, p. 174, DOI: 10.1161/01.CIR.104.2.174 63 10.1161/01.CIR.104.2.174 false true Reference 20129115 /api/reference/20129115 64. Vona 2019: Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases, Oxid. Med. Cell. Longev., p. 1, DOI: 10.1155/2019/8267234 64 10.1155/2019/8267234 false true Reference 20129116 /api/reference/20129116 65. Dhalla 2014: Mechanisms of subcellular remodeling in heart failure due to diabetes, Heart Fail. Rev., 19, p. 87, DOI: 10.1007/s10741-013-9385-8 65 10.1007/s10741-013-9385-8 false true Reference 20129117 /api/reference/20129117 66. Canton 2011: Oxidation of Myofibrillar Proteins in Human Heart Failure, J. Am. Coll. Cardiol., 57, p. 300, DOI: 10.1016/j.jacc.2010.06.058 66 10.1016/j.jacc.2010.06.058 false true Reference 20129118 /api/reference/20129118 67. Saini 2004: Role of cholesterol in cardiovascular dysfunction, Can. J. Cardiol., 20, p. 333 67 false true Reference 20129119 /api/reference/20129119 68. Burns 2002: Plant Foods and Herbal Sources of Resveratrol, J. Agric. Food Chem., 50, p. 3337, DOI: 10.1021/jf0112973 68 10.1021/jf0112973 false true Reference 20129120 /api/reference/20129120 69. Sulaiman 2010: Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy, Am. J. Physiol. Circ. Physiol., 298, p. H833, DOI: 10.1152/ajpheart.00418.2009 69 10.1152/ajpheart.00418.2009 false true Reference 20129121 /api/reference/20129121 70. Ma 2017: SIRT1 Activation by Resveratrol Alleviates Cardiac Dysfunction via Mitochondrial Regulation in Diabetic Cardiomyopathy Mice, Oxid. Med. Cell. Longev., p. 1 70 false true Reference 20129122 /api/reference/20129122 71. Mohammadshahi 2014: Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress, Cardiol. J., 21, p. 39, DOI: 10.5603/CJ.a2013.0051 71 10.5603/CJ.a2013.0051 false true Reference 20129123 /api/reference/20129123 72. Wang 2018: Resveratrol Prevents Diabetic Cardiomyopathy by Increasing Nrf2 Expression and Transcriptional Activity, Biomed Res. Int., p. 1 72 false true Reference 20129124 /api/reference/20129124 73. Fang 2018: Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation, Acta Pharmacol. Sin., 39, p. 59, DOI: 10.1038/aps.2017.50 73 10.1038/aps.2017.50 false true Reference 20129125 /api/reference/20129125 74. Beaudoin 2014: Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats, J. Physiol., 592, p. 2519, DOI: 10.1113/jphysiol.2013.270538 74 10.1113/jphysiol.2013.270538 false true Reference 20129126 /api/reference/20129126 75. Wang 2014: Resveratrol‐enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice, J. Cell. Mol. Med., 18, p. 1599, DOI: 10.1111/jcmm.12312 75 10.1111/jcmm.12312 false true Reference 20129127 /api/reference/20129127 76. Wu 2017: Resveratrol Ameliorates Cardiac Dysfunction by Inhibiting Apoptosis via the PI3K/Akt/FoxO3a Pathway in a Rat Model of Diabetic Cardiomyopathy, J. Cardiovasc. Pharmacol., 70, p. 184, DOI: 10.1097/FJC.0000000000000504 76 10.1097/FJC.0000000000000504 false true Reference 20129128 /api/reference/20129128 77. ShamsEldeen 2019: Combined treatment with systemic resveratrol and resveratrol preconditioned mesenchymal stem cells, maximizes antifibrotic action in diabetic cardiomyopathy, J. Cell. Physiol., 234, p. 10942, DOI: 10.1002/jcp.27947 77 10.1002/jcp.27947 false true Reference 20129129 /api/reference/20129129 78. Thirunavukkarasu 2007: Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase, Free Radic. Biol. Med., 43, p. 720, DOI: 10.1016/j.freeradbiomed.2007.05.004 78 10.1016/j.freeradbiomed.2007.05.004 false true Reference 20129130 /api/reference/20129130 79. Fourny 2019: Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart, Nutrients, 11, p. 105, DOI: 10.3390/nu11010105 79 10.3390/nu11010105 false true Reference 20129131 /api/reference/20129131 80. Qu 2019: Resveratrol alleviates ischemia/reperfusion injury of diabetic myocardium via inducing autophagy, Exp. Ther. Med., DOI: 10.3892/etm.2019.7846 80 10.3892/etm.2019.7846 false true Reference 20129132 /api/reference/20129132 81. Xu 2019: Resveratrol increase myocardial Nrf2 expression in type 2 diabetic rats and alleviate myocardial ischemia/reperfusion injury (MIRI), Ann. Palliat. Med., 8, p. 565, DOI: 10.21037/apm.2019.11.25 81 10.21037/apm.2019.11.25 false true Reference 20129133 /api/reference/20129133 82. Mozafari 2015: The cardioprotective effects of resveratrol in rats with simultaneous type 2 diabetes and renal hypertension, Nat Prod Commun, 10, p. 335 82 false true Reference 20129134 /api/reference/20129134 83. Huo 2019: Resveratrol Effects on a Diabetic Rat Model with Coronary Heart Disease, Med. Sci. Monit., 25, p. 540, DOI: 10.12659/MSM.910996 83 10.12659/MSM.910996 false true Reference 20129135 /api/reference/20129135 84. Dekkers 2008: Identification by a differential proteomic approach of the induced stress and redox proteins by resveratrol in the normal and diabetic rat heart, J. Cell. Mol. Med., 12, p. 1677, DOI: 10.1111/j.1582-4934.2008.00227.x 84 10.1111/j.1582-4934.2008.00227.x false true Reference 20129136 /api/reference/20129136 85. Huang 2010: Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin, Free Radic. Biol. Med., 49, p. 1710, DOI: 10.1016/j.freeradbiomed.2010.08.032 85 10.1016/j.freeradbiomed.2010.08.032 false true Reference 20129137 /api/reference/20129137 86. Lekli 2008: Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin, Am. J. Physiol. Circ. Physiol., 294, p. H859, DOI: 10.1152/ajpheart.01048.2007 86 10.1152/ajpheart.01048.2007 false true Reference 20129138 /api/reference/20129138 87. MIATELLO 2005: Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats, Am. J. Hypertens., 18, p. 864, DOI: 10.1016/j.amjhyper.2004.12.012 87 10.1016/j.amjhyper.2004.12.012 false true Reference 20129139 /api/reference/20129139 88. Robich 2011: Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia, Eur. J. Pharmacol., 664, p. 45, DOI: 10.1016/j.ejphar.2011.04.059 88 10.1016/j.ejphar.2011.04.059 false true Reference 20129140 /api/reference/20129140 89. Robich 2012: Resveratrol Preserves Myocardial Function and Perfusion in Remote Nonischemic Myocardium in a Swine Model of Metabolic Syndrome, J. Am. Coll. Surg., 215, p. 681, DOI: 10.1016/j.jamcollsurg.2012.06.417 89 10.1016/j.jamcollsurg.2012.06.417 false true Reference 20129141 /api/reference/20129141 90. Sabe 2013: Does resveratrol improve insulin signaling in chronically ischemic myocardium?, J. Surg. Res., 183, p. 531, DOI: 10.1016/j.jss.2013.03.004 90 10.1016/j.jss.2013.03.004 false true Reference 20129142 /api/reference/20129142 91. Meng 2014: Cardioprotective effect of resveratrol on atherogenic diet-fed rats, Int. J. Clin. Exp. Pathol., 7, p. 7899 91 false true Reference 20129143 /api/reference/20129143 92. Robich 2010: Resveratrol Improves Myocardial Perfusion in a Swine Model of Hypercholesterolemia and Chronic Myocardial Ischemia, Circulation, 122, p. S142, DOI: 10.1161/CIRCULATIONAHA.109.920132 92 10.1161/CIRCULATIONAHA.109.920132 false true Reference 20129144 /api/reference/20129144 93. Juhaz 2011: Reduction of blood cholesterol and ischemic injury in the hypercholesteromic rabbits with modified resveratrol, logevinex, Mol. Cell. Biochem., 348, p. 199, DOI: 10.1007/s11010-010-0615-2 93 10.1007/s11010-010-0615-2 false true Reference 20129145 /api/reference/20129145 94. Das 2015: Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy, Sci. Rep., 5, p. 18132, DOI: 10.1038/srep18132 94 10.1038/srep18132 false true Reference 20129146 /api/reference/20129146 95. Das 2018: Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy, Biosci. Rep., 38, DOI: 10.1042/BSR20171302 95 10.1042/BSR20171302 false true Reference 20129147 /api/reference/20129147 96. Imamura 2017: Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus, Int. Heart J., 58, p. 577, DOI: 10.1536/ihj.16-373 96 10.1536/ihj.16-373 false true Reference 20129148 /api/reference/20129148 97. Chekalina 2017: Resveratrol has a positive effect on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease, Wiad Lek, 70, p. 286 97 false true Reference 20129149 /api/reference/20129149 98. Gal 2020: Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol, Cardiovasc. Ther., 2020, p. 1, DOI: 10.1155/2020/7262474 98 10.1155/2020/7262474 false true Reference 20129150 /api/reference/20129150 99. Sergi 2020: Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials, Arch. Med. Sci. - Atheroscler. Dis., 5, p. 98, DOI: 10.5114/amsad.2020.95884 99 10.5114/amsad.2020.95884 false true Reference 20129151 /api/reference/20129151 100. Ferenczyova 2020: Potential Implications of Quercetin and its Derivatives in Cardioprotection, Int. J. Mol. Sci., 21, p. 1585, DOI: 10.3390/ijms21051585 100 10.3390/ijms21051585 false true Reference 20129152 /api/reference/20129152 101. Castillo 2018: Quercetin Prevents Diastolic Dysfunction Induced by a High-Cholesterol Diet: Role of Oxidative Stress and Bioenergetics in Hyperglycemic Rats, Oxid. Med. Cell. Longev., p. 1, DOI: 10.1155/2018/7239123 101 10.1155/2018/7239123 false true Reference 20129153 /api/reference/20129153 102. Panchal 2012: Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats, J. Nutr., 142, p. 1026, DOI: 10.3945/jn.111.157263 102 10.3945/jn.111.157263 false true Reference 20129154 /api/reference/20129154 103. Sun 2014: Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis, Food Chem. Toxicol., 63, p. 221, DOI: 10.1016/j.fct.2013.11.013 103 10.1016/j.fct.2013.11.013 false true Reference 20129155 /api/reference/20129155 104. Liu 2020: Spiraeoside protects human cardiomyocytes against high glucose‐induced injury, oxidative stress, and apoptosis by activation of PI3K/Akt/Nrf2 pathway, J. Biochem. Mol. Toxicol., 34, DOI: 10.1002/jbt.22548 104 10.1002/jbt.22548 false true Reference 20129156 /api/reference/20129156 105. Annapurna 2009: Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin-induced type I diabetic rats, J. Pharm. Pharmacol., 61, p. 1365, DOI: 10.1211/jpp.61.10.0014 105 10.1211/jpp.61.10.0014 false true Reference 20129157 /api/reference/20129157 106. Najafi 2018: Anti-arrhythmogenic and anti-inflammatory effects of troxerutin in ischemia/reperfusion injury of diabetic myocardium, Biomed. Pharmacother., 102, p. 385, DOI: 10.1016/j.biopha.2018.03.047 106 10.1016/j.biopha.2018.03.047 false true Reference 20129158 /api/reference/20129158 107. Mokhtari 2015: Phosphorylation of GSK-3β and reduction of apoptosis as targets of troxerutin effect on reperfusion injury of diabetic myocardium, Eur. J. Pharmacol., 765, p. 316, DOI: 10.1016/j.ejphar.2015.08.056 107 10.1016/j.ejphar.2015.08.056 false true Reference 20129159 /api/reference/20129159 108. Barteková 2010: Acute treatment with polyphenol quercetin improves postischemic recovery of isolated perfused rat hearts after global ischemia, Can. J. Physiol. Pharmacol., 88, p. 465, DOI: 10.1139/Y10-025 108 10.1139/Y10-025 false true Reference 20129160 /api/reference/20129160 109. Barteková 2015: Quercetin Improves Postischemic Recovery of Heart Function in Doxorubicin-Treated Rats and Prevents Doxorubicin-Induced Matrix Metalloproteinase-2 Activation and Apoptosis Induction, Int. J. Mol. Sci., 16, p. 8168, DOI: 10.3390/ijms16048168 109 10.3390/ijms16048168 false true Reference 20129161 /api/reference/20129161 110. Ferenczyova 2020: Quercetin Exerts Age-Dependent Beneficial Effects on Blood Pressure and Vascular Function, But Is Inefficient in Preventing Myocardial Ischemia-Reperfusion Injury in Zucker Diabetic Fatty Rats, Molecules, 25, p. 187, DOI: 10.3390/molecules25010187 110 10.3390/molecules25010187 false true Reference 20129162 /api/reference/20129162 111. Prabu 2013: Quercetin potentially attenuates cadmium induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats, Eur Rev Med Pharmacol Sci, 17, p. 582 111 false true Reference 20129163 /api/reference/20129163 112. Ulasova 2013: Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse, Redox Biol, 1, p. 381, DOI: 10.1016/j.redox.2013.07.001 112 10.1016/j.redox.2013.07.001 false true Reference 20129164 /api/reference/20129164 113. Shen 2013: Dietary quercetin attenuates oxidant-induced endothelial dysfunction and atherosclerosis in apolipoprotein E knockout mice fed a high-fat diet: A critical role for heme oxygenase-1, Free Radic. Biol. Med., 65, p. 908, DOI: 10.1016/j.freeradbiomed.2013.08.185 113 10.1016/j.freeradbiomed.2013.08.185 false true Reference 20129165 /api/reference/20129165 114. Pashevin 2011: Antiatherogenic effect of quercetin is mediated by proteasome inhibition in the aorta and circulating leukocytes, Pharmacol. Reports, 63, p. 1009, DOI: 10.1016/S1734-1140(11)70617-X 114 10.1016/S1734-1140(11)70617-X false true Reference 20129166 /api/reference/20129166 115. Zhang 2011: Protective effects of baicalin and quercetin on an iron-overloaded mouse: comparison of liver, kidney and heart tissues, Nat. Prod. Res., 25, p. 1150, DOI: 10.1080/14786419.2010.495070 115 10.1080/14786419.2010.495070 false true Reference 20129167 /api/reference/20129167 116. Malishevskaia IV 2013: [Therapeutic efficacy of quercetin in patients with is ischemic heart disease with underlying metabolic syndrome], Georg. Med News., 225, p. 67 116 false true Reference 20129168 /api/reference/20129168 117. Shi 2016: Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial, Br. J. Nutr., 115, p. 800, DOI: 10.1017/S0007114515005310 117 10.1017/S0007114515005310 false true Reference 20129169 /api/reference/20129169 118. Manach 2004: Polyphenols: food sources and bioavailability, Am. J. Clin. Nutr., 79, p. 727, DOI: 10.1093/ajcn/79.5.727 118 10.1093/ajcn/79.5.727 false true Reference 20129170 /api/reference/20129170 119. Li 2018: (-)-Epicatechin protects against myocardial ischemia-induced cardiac injury via activation of the PTEN/PI3K/AKT pathway, Mol. Med. Rep., 17, p. 8300 119 false true Reference 20129171 /api/reference/20129171 120. Ortiz-Vilchis 2018: The cardioprotective effects of (-)-Epicatechin are mediated through arginase activity inhibition in a murine model of ischemia/reperfusion, Eur. J. Pharmacol., 818, p. 335, DOI: 10.1016/j.ejphar.2017.11.007 120 10.1016/j.ejphar.2017.11.007 false true Reference 20129172 /api/reference/20129172 121. Othman 2017: Epigallocatechin-3-gallate protects against diabetic cardiomyopathy through modulating the cardiometabolic risk factors, oxidative stress, inflammation, cell death and fibrosis in streptozotocin-nicotinamide-induced diabetic rats, Biomed. Pharmacother., 94, p. 362, DOI: 10.1016/j.biopha.2017.07.129 121 10.1016/j.biopha.2017.07.129 false true Reference 20129173 /api/reference/20129173 122. Cong 2020: Catechin relieves hypoxia/reoxygenation‐induced myocardial cell apoptosis via down‐regulating lncRNA MIAT, J. Cell. Mol. Med., 24, p. 2356, DOI: 10.1111/jcmm.14919 122 10.1111/jcmm.14919 false true Reference 20129174 /api/reference/20129174 123. Lin 2020: (-)-Epigallocatechin Gallate Promotes MicroRNA 145 Expression against Myocardial Hypoxic Injury through Dab2/Wnt3a/β-catenin, Am. J. Chin. Med., 48, p. 341, DOI: 10.1142/S0192415X20500172 123 10.1142/S0192415X20500172 false true Reference 20129175 /api/reference/20129175 124. Othman 2017: Epigallocatechin-3-gallate prevents cardiac apoptosis by modulating the intrinsic apoptotic pathway in isoproterenol-induced myocardial infarction, Eur. J. Pharmacol., 794, p. 27, DOI: 10.1016/j.ejphar.2016.11.014 124 10.1016/j.ejphar.2016.11.014 false true Reference 20129176 /api/reference/20129176 125. Wu 2017: (−)-Epigallocatechin-3-gallate attenuates myocardial injury induced by ischemia/reperfusion in diabetic rats and in H9c2 cells under hyperglycemic conditions, Int. J. Mol. Med., 40, p. 389, DOI: 10.3892/ijmm.2017.3014 125 10.3892/ijmm.2017.3014 false true Reference 20129177 /api/reference/20129177 126. Ramesh 2008: Epigallocatechin gallate improves serum lipid profile and erythrocyte and cardiac tissue antioxidant parameters in Wistar rats fed an atherogenic diet, Fundam. Clin. Pharmacol., 22, p. 275, DOI: 10.1111/j.1472-8206.2008.00585.x 126 10.1111/j.1472-8206.2008.00585.x false true Reference 20129178 /api/reference/20129178 127. Townsend 2018: Epigallocatechin-3-gallate remodels apolipoprotein A-I amyloid fibrils into soluble oligomers in the presence of heparin, J. Biol. Chem., 293, p. 12877, DOI: 10.1074/jbc.RA118.002038 127 10.1074/jbc.RA118.002038 false true Reference 20129179 /api/reference/20129179 128. Gendron 2010: Late chronic catechin antioxidant treatment is deleterious to the endothelial function in aging mice with established atherosclerosis, Am. J. Physiol. Circ. Physiol., 298, p. H2062, DOI: 10.1152/ajpheart.00532.2009 128 10.1152/ajpheart.00532.2009 false true Reference 20129180 /api/reference/20129180 129. Al Hroob 2019: Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate, Biomed. Pharmacother., 109, p. 2155, DOI: 10.1016/j.biopha.2018.11.086 129 10.1016/j.biopha.2018.11.086 false true Reference 20129181 /api/reference/20129181 130. Ak 2008: Antioxidant and radical scavenging properties of curcumin, Chem. Biol. Interact., 174, p. 27, DOI: 10.1016/j.cbi.2008.05.003 130 10.1016/j.cbi.2008.05.003 false true Reference 20129182 /api/reference/20129182 131. Soetikno 2012: Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: Possible involvement of PKC–MAPK signaling pathway, Eur. J. Pharm. Sci., 47, p. 604, DOI: 10.1016/j.ejps.2012.04.018 131 10.1016/j.ejps.2012.04.018 false true Reference 20129183 /api/reference/20129183 132. Gbr 2020: Cardioprotective effect of pioglitazone and curcumin against diabetic cardiomyopathy in type 1 diabetes mellitus: impact on CaMKII/NF-κB/TGF-β1 and PPAR-γ signaling pathway, Naunyn. Schmiedebergs. Arch. Pharmacol. 132 false true Reference 20129184 /api/reference/20129184 133. Abdel-Mageid 2018: The potential effect of garlic extract and curcumin nanoparticles against complication accompanied with experimentally induced diabetes in rats, Phytomedicine, 43, p. 126, DOI: 10.1016/j.phymed.2018.04.039 133 10.1016/j.phymed.2018.04.039 false true Reference 20129185 /api/reference/20129185 134. Li 2019: Tetrahydrocurcumin Ameliorates Diabetic Cardiomyopathy by Attenuating High Glucose-Induced Oxidative Stress and Fibrosis via Activating the SIRT1 Pathway, Oxid. Med. Cell. Longev., p. 1 134 false true Reference 20129186 /api/reference/20129186 135. Li 2018: Cardioprotective effects of the novel curcumin analogue C66 in diabetic mice is dependent on JNK2 inactivation, J. Cell. Mol. Med., 22, p. 6314, DOI: 10.1111/jcmm.13924 135 10.1111/jcmm.13924 false true Reference 20129187 /api/reference/20129187 136. Guo 2018: Curcumin administration suppresses collagen synthesis in the hearts of rats with experimental diabetes, Acta Pharmacol. Sin., 39, p. 195, DOI: 10.1038/aps.2017.92 136 10.1038/aps.2017.92 false true Reference 20129188 /api/reference/20129188 137. Ren 2020: Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1‐Foxo1 and PI3K‐Akt signalling pathways, J. Cell. Mol. Med., 24, p. 12355, DOI: 10.1111/jcmm.15725 137 10.1111/jcmm.15725 false true Reference 20129189 /api/reference/20129189 138. Xiang 2020: Curcumin analog A13 alleviates oxidative stress by activating Nrf2/ARE pathway and ameliorates fibrosis in the myocardium of high-fat-diet and streptozotocin-induced diabetic rats, Diabetol. Metab. Syndr., 12, p. 1, DOI: 10.1186/s13098-019-0485-z 138 10.1186/s13098-019-0485-z false true Reference 20129190 /api/reference/20129190 139. Yao 2018: Curcumin protects against diabetic cardiomyopathy by promoting autophagy and alleviating apoptosis, J. Mol. Cell. Cardiol., 124, p. 26, DOI: 10.1016/j.yjmcc.2018.10.004 139 10.1016/j.yjmcc.2018.10.004 false true Reference 20129191 /api/reference/20129191 140. Yan 2020: Blockade of high mobility group box 1 involved in the protective of curcumin on myocardial injury in diabetes in vivo and in vitro, IUBMB Life, 72, p. 931, DOI: 10.1002/iub.2226 140 10.1002/iub.2226 false true Reference 20129192 /api/reference/20129192 141. Wu 2020: Curcumin protects cardiomyopathy damage through inhibiting the production of reactive oxygen species in type 2 diabetic mice, Biochem. Biophys. Res. Commun., 530, p. 15, DOI: 10.1016/j.bbrc.2020.05.053 141 10.1016/j.bbrc.2020.05.053 false true Reference 20129193 /api/reference/20129193 142. Lv 2020: Curcumin inhibits the formation of atherosclerosis in ApoE mice by suppressing cytomegalovirus activity in endothelial cells, Life Sci, 257, DOI: 10.1016/j.lfs.2020.117658 142 10.1016/j.lfs.2020.117658 false true Reference 20129194 /api/reference/20129194 143. Li 2015: Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model, Int. J. Clin. Exp. Pathol., 8, p. 7247 143 false true Reference 20129195 /api/reference/20129195 144. Kapoor 2008: Modulatory effect of curcumin on methionine-induced hyperlipidemia and hyperhomocysteinemia in albino rats, Indian J Exp Biol, 46, p. 534 144 false true Reference 20129196 /api/reference/20129196 145. Bupparenoo 2020: Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial, J. Diet. Suppl., p. 1, DOI: 10.1080/19390211.2020.1757798 145 10.1080/19390211.2020.1757798 false true Reference 20129197 /api/reference/20129197 146. Efentakis 2015: Effects of the Olive Tree Leaf Constituents on Myocardial Oxidative Damage and Atherosclerosis, Planta Med, 81, p. 648, DOI: 10.1055/s-0035-1546017 146 10.1055/s-0035-1546017 false true Reference 20129198 /api/reference/20129198 147. Nekooeian 2014: Oleuropein offers cardioprotection in rats with simultaneous type 2 diabetes and renal hypertension, Indian J. Pharmacol., 46, p. 398, DOI: 10.4103/0253-7613.135951 147 10.4103/0253-7613.135951 false true Reference 20129199 /api/reference/20129199 148. Andreadou 2006: The Olive Constituent Oleuropein Exhibits Anti-Ischemic, Antioxidative, and Hypolipidemic Effects in Anesthetized Rabbits, J. Nutr., 136, p. 2213, DOI: 10.1093/jn/136.8.2213 148 10.1093/jn/136.8.2213 false true Reference 20129200 /api/reference/20129200 149. Andreadou 2014: The Natural Olive Constituent Oleuropein Induces Nutritional Cardioprotection in Normal and Cholesterol-Fed Rabbits: Comparison with Preconditioning, Planta Med, 81, p. 655, DOI: 10.1055/s-0034-1383306 149 10.1055/s-0034-1383306 false true Reference 20129201 /api/reference/20129201 150. Poudyal 2017: Hydroxytyrosol ameliorates metabolic, cardiovascular and liver changes in a rat model of diet-induced metabolic syndrome: Pharmacological and metabolism-based investigation, Pharmacol. Res., 117, p. 32, DOI: 10.1016/j.phrs.2016.12.002 150 10.1016/j.phrs.2016.12.002 false true Reference 20129202 /api/reference/20129202 151. Fitó 2014: Effect of the Mediterranean diet on heart failure biomarkers: a randomized sample from the PREDIMED trial, Eur. J. Heart Fail., 16, p. 543, DOI: 10.1002/ejhf.61 151 10.1002/ejhf.61 false true Reference 20129203 /api/reference/20129203 152. Casas 2014: The Effects of the Mediterranean Diet on Biomarkers of Vascular Wall Inflammation and Plaque Vulnerability in Subjects with High Risk for Cardiovascular Disease. A Randomized Trial, PLoS One, 9, DOI: 10.1371/journal.pone.0100084 152 10.1371/journal.pone.0100084 false true Reference 20129204 /api/reference/20129204 153. Papadaki 2017: Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial, Eur. J. Heart Fail., 19, p. 1179, DOI: 10.1002/ejhf.750 153 10.1002/ejhf.750 false true Reference 20129205 /api/reference/20129205 154. Zhang 2019: The protective effect of kaempferol on heart via the regulation of Nrf2, NF‐κβ, and PI3K/Akt/GSK‐3β signaling pathways in isoproterenol‐induced heart failure in diabetic rats, Drug Dev. Res., 80, p. 294, DOI: 10.1002/ddr.21495 154 10.1002/ddr.21495 false true Reference 20129206 /api/reference/20129206 155. Chen 2018: Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress, Endocrine, 60, p. 83, DOI: 10.1007/s12020-018-1525-4 155 10.1007/s12020-018-1525-4 false true Reference 20129207 /api/reference/20129207 156. Suchal 2017: Molecular Pathways Involved in the Amelioration of Myocardial Injury in Diabetic Rats by Kaempferol, Int. J. Mol. Sci., 18, p. 1001, DOI: 10.3390/ijms18051001 156 10.3390/ijms18051001 false true Reference 20129208 /api/reference/20129208 157. Al-Numair 2015: Influence of kaempferol, a flavonoid compound, on membrane-bound ATPases in streptozotocin-induced diabetic rats, Pharm. Biol., 53, p. 1372, DOI: 10.3109/13880209.2014.982301 157 10.3109/13880209.2014.982301 false true Reference 20129209 /api/reference/20129209 158. CHEN 2014: Inhibition of the leptin-induced activation of the p38 MAPK pathway contributes to the protective effects of naringin against high glucose-induced injury in H9c2 cardiac cells, Int. J. Mol. Med., 33, p. 605, DOI: 10.3892/ijmm.2014.1614 158 10.3892/ijmm.2014.1614 false true Reference 20129210 /api/reference/20129210 159. You 2016: Naringin protects cardiomyocytes against hyperglycemia-induced injuries in vitro and in vivo, J. Endocrinol., 230, p. 197, DOI: 10.1530/JOE-16-0004 159 10.1530/JOE-16-0004 false true Reference 20129211 /api/reference/20129211 160. Adebiyi 2016: Naringin Reduces Hyperglycemia-Induced Cardiac Fibrosis by Relieving Oxidative Stress, PLoS One, 11, DOI: 10.1371/journal.pone.0149890 160 10.1371/journal.pone.0149890 false true Reference 20129212 /api/reference/20129212 161. Sun 2012: Luteolin Limits Infarct Size and Improves Cardiac Function after Myocardium Ischemia/Reperfusion Injury in Diabetic Rats, PLoS One, 7 161 false true Reference 20129213 /api/reference/20129213 162. Yang 2015: Cardioprotective Effects of Luteolin on Ischemia/Reperfusion Injury in Diabetic Rats Are Modulated by eNOS and the Mitochondrial Permeability Transition Pathway, J. Cardiovasc. Pharmacol., 65, p. 349, DOI: 10.1097/FJC.0000000000000202 162 10.1097/FJC.0000000000000202 false true Reference 20129214 /api/reference/20129214 163. Xiao 2019: Luteolin Attenuates Cardiac Ischemia/Reperfusion Injury in Diabetic Rats by Modulating Nrf2 Antioxidative Function, Oxid. Med. Cell. Longev., p. 1 163 false true Reference 20129215 /api/reference/20129215 164. Li 2019: Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses, Phytomedicine, 59, DOI: 10.1016/j.phymed.2018.11.034 164 10.1016/j.phymed.2018.11.034 false true Reference 20129216 /api/reference/20129216 165. Duan 2017: Protective effect of butin against ischemia/reperfusion-induced myocardial injury in diabetic mice: involvement of the AMPK/GSK-3β/Nrf2 signaling pathway, Sci. Rep., 7, p. 41491, DOI: 10.1038/srep41491 165 10.1038/srep41491 false true Reference 20129217 /api/reference/20129217 166. Tsai 2018: Tanshinone IIA Inhibits High Glucose-Induced Collagen Synthesis via Nuclear Factor Erythroid 2-Related Factor 2 in Cardiac Fibroblasts, Cell, Physiol. Biochem., 51, p. 2250 166 false true Reference 20129218 /api/reference/20129218 167. Okutan 2005: Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart, Clin. Biochem., 38, p. 191, DOI: 10.1016/j.clinbiochem.2004.10.003 167 10.1016/j.clinbiochem.2004.10.003 false true Reference 20129219 /api/reference/20129219 168. Li 2019: Effect of CAPE-pNO2 against type 2 diabetes mellitus via the AMPK/GLUT4/GSK3β/PPARα pathway in HFD/STZ-induced diabetic mice, Eur. J. Pharmacol., 853, p. 1, DOI: 10.1016/j.ejphar.2019.03.027 168 10.1016/j.ejphar.2019.03.027 false true Reference 20129220 /api/reference/20129220 169. Park 2006: Caffeic acid phenethyl ester ameliorates changes in IGFs secretion and gene expression in streptozotocin-induced diabetic rats, Life Sci, 78, p. 1741, DOI: 10.1016/j.lfs.2005.08.011 169 10.1016/j.lfs.2005.08.011 false true Reference 20129221 /api/reference/20129221 170. Ho 2014: Caffeic acid phenethyl amide ameliorates ischemia/reperfusion injury and cardiac dysfunction in streptozotocin-induced diabetic rats, Cardiovasc. Diabetol., 13, p. 98, DOI: 10.1186/1475-2840-13-98 170 10.1186/1475-2840-13-98 false true Reference 20129222 /api/reference/20129222 171. Ho 2013: Caffeic acid phenethyl amide improves glucose homeostasis and attenuates the progression of vascular dysfunction in Streptozotocin-induced diabetic rats, Cardiovasc. Diabetol., 12, p. 99, DOI: 10.1186/1475-2840-12-99 171 10.1186/1475-2840-12-99 false true Reference 20129223 /api/reference/20129223 172. Houghton 2013: Sulforaphane: translational research from laboratory bench to clinic, Nutr. Rev., 71, p. 709, DOI: 10.1111/nure.12060 172 10.1111/nure.12060 false true Reference 20129224 /api/reference/20129224 173. Bai 2013: Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation, J. Mol. Cell. Cardiol., 57, p. 82, DOI: 10.1016/j.yjmcc.2013.01.008 173 10.1016/j.yjmcc.2013.01.008 false true Reference 20129225 /api/reference/20129225 174. Xu 2016: Broccoli sprout extract prevents diabetic cardiomyopathy via Nrf2 activation in db/db T2DM mice, Sci. Rep., 6, p. 30252, DOI: 10.1038/srep30252 174 10.1038/srep30252 false true Reference 20129226 /api/reference/20129226 175. Gu 2017: Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy, Diabetes, 66, p. 529, DOI: 10.2337/db15-1274 175 10.2337/db15-1274 false true Reference 20129227 /api/reference/20129227 176. Wang 2019: Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice, J. Cell. Mol. Med., 23, p. 6319, DOI: 10.1111/jcmm.14520 176 10.1111/jcmm.14520 false true Reference 20129228 /api/reference/20129228 177. Huang 2013: Diallyl trisulfide and diallyl disulfide ameliorate cardiac dysfunction by suppressing apoptotic and enhancing survival pathways in experimental diabetic rats, J. Appl. Physiol., 114, p. 402, DOI: 10.1152/japplphysiol.00672.2012 177 10.1152/japplphysiol.00672.2012 false true Reference 20129229 /api/reference/20129229 178. Carr 1999: Does vitamin C act as a pro‐oxidant under physiological conditions?, FASEB J, 13, p. 1007, DOI: 10.1096/fasebj.13.9.1007 178 10.1096/fasebj.13.9.1007 false true Reference 20129230 /api/reference/20129230 179. Padayatty 2003: Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention, J. Am. Coll. Nutr., 22, p. 18, DOI: 10.1080/07315724.2003.10719272 179 10.1080/07315724.2003.10719272 false true Reference 20129231 /api/reference/20129231 180. Wold 2004: Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism, Biochem. Biophys. Res. Commun., 318, p. 1066, DOI: 10.1016/j.bbrc.2004.04.138 180 10.1016/j.bbrc.2004.04.138 false true Reference 20129232 /api/reference/20129232 181. Okazaki 2011: Ascorbic acid and N-acetyl cysteine prevent uncoupling of nitric oxide synthase and increase tolerance to ischemia/reperfusion injury in diabetic rat heart, Free Radic. Res., 45, p. 1173, DOI: 10.3109/10715762.2011.605361 181 10.3109/10715762.2011.605361 false true Reference 20129233 /api/reference/20129233 182. Wenzel 2005: No correlation between the p38 MAPK pathway and the contractile dysfunction in diabetic cardiomyocytes, Pflügers Arch. - Eur. J. Physiol., 451, p. 328, DOI: 10.1007/s00424-005-1476-5 182 10.1007/s00424-005-1476-5 false true Reference 20129234 /api/reference/20129234 183. Saran 2014: Combined metoprolol and ascorbic acid treatment prevents intrinsic damage to the heart during diabetic cardiomyopathy, Can. J. Physiol. Pharmacol., 92, p. 827, DOI: 10.1139/cjpp-2014-0078 183 10.1139/cjpp-2014-0078 false true Reference 20129235 /api/reference/20129235 184. Boyacioglu 2014: The protective effects of vitamin C on the DNA damage, antioxidant defenses and aorta histopathology in chronic hyperhomocysteinemia induced rats, Exp. Toxicol. Pathol., 66, p. 407, DOI: 10.1016/j.etp.2014.06.004 184 10.1016/j.etp.2014.06.004 false true Reference 20129236 /api/reference/20129236 185. Jenner 2000: Ascorbic acid supplementation does not lower plasma lipoprotein(a) concentrations, Atherosclerosis, 151, p. 541, DOI: 10.1016/S0021-9150(99)00424-4 185 10.1016/S0021-9150(99)00424-4 false true Reference 20129237 /api/reference/20129237 186. Hirai 2000: Insulin resistance and endothelial dysfunction in smokers: effects of vitamin C, Am. J. Physiol. Circ. Physiol., 279, p. H1172, DOI: 10.1152/ajpheart.2000.279.3.H1172 186 10.1152/ajpheart.2000.279.3.H1172 false true Reference 20129238 /api/reference/20129238 187. Widlansky 2004: Coronary endothelial dysfunction is not rapidly reversible with ascorbic acid, Free Radic. Biol. Med., 36, p. 123, DOI: 10.1016/j.freeradbiomed.2003.10.016 187 10.1016/j.freeradbiomed.2003.10.016 false true Reference 20129239 /api/reference/20129239 188. McRae 2008: Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials, J. Chiropr. Med., 7, p. 48, DOI: 10.1016/j.jcme.2008.01.002 188 10.1016/j.jcme.2008.01.002 false true Reference 20129240 /api/reference/20129240 189. Mason 2021: Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials, Diabetes Care, 44, p. 618, DOI: 10.2337/dc20-1893 189 10.2337/dc20-1893 false true Reference 20129241 /api/reference/20129241 190. Bostom 1994: High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease, Atherosclerosis, 111, p. 267, DOI: 10.1016/0021-9150(94)90101-5 190 10.1016/0021-9150(94)90101-5 false true Reference 20129242 /api/reference/20129242 191. Peng 2018: Effect of Oral Vitamin C Supplementation on High-Altitude Hyperuricemia in Young Men Initially Migrating to High Altitude: A Pilot Study, High Alt. Med. Biol., 19, p. 373, DOI: 10.1089/ham.2018.0058 191 10.1089/ham.2018.0058 false true Reference 20129243 /api/reference/20129243 192. El Mashad 2016: Effect of vitamin C supplementation on lipid profile, serum uric acid, and ascorbic acid in children on hemodialysis, Saudi J. Kidney Dis. Transplant., 27, p. 1148, DOI: 10.4103/1319-2442.194602 192 10.4103/1319-2442.194602 false true Reference 20129244 /api/reference/20129244 193. 1999: High-dose Vitamin C: A Risk for Persons with High Iron Stores?, Int. J. Vitam. Nutr. Res., 69, p. 67, DOI: 10.1024/0300-9831.69.2.67 193 10.1024/0300-9831.69.2.67 false true Reference 20129245 /api/reference/20129245 194. Traber 2007: Vitamin E, antioxidant and nothing more, Free Radic. Biol. Med., 43, p. 4, DOI: 10.1016/j.freeradbiomed.2007.03.024 194 10.1016/j.freeradbiomed.2007.03.024 false true Reference 20129246 /api/reference/20129246 195. Mah 2015: bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial, Am. J. Clin. Nutr., 102, p. 1070, DOI: 10.3945/ajcn.115.118570 195 10.3945/ajcn.115.118570 false true Reference 20129247 /api/reference/20129247 196. Wong 2017: Anti-inflammatory γ- and δ-tocotrienols improve cardiovascular, liver and metabolic function in diet-induced obese rats, Eur. J. Nutr., 56, p. 133, DOI: 10.1007/s00394-015-1064-1 196 10.1007/s00394-015-1064-1 false true Reference 20129248 /api/reference/20129248 197. Sakuraba 1987: Effect of vitamin E and ticlopidine on platelet aggregation in Fabry’s disease, Clin. Genet., 31, p. 349, DOI: 10.1111/j.1399-0004.1987.tb02820.x 197 10.1111/j.1399-0004.1987.tb02820.x false true Reference 20129249 /api/reference/20129249 198. Meléndez‐Martínez 2019: An Overview of Carotenoids, Apocarotenoids, and Vitamin A in Agro‐Food, Nutrition, Health, and Disease, Mol. Nutr. Food Res., 63, DOI: 10.1002/mnfr.201801045 198 10.1002/mnfr.201801045 false true Reference 20129250 /api/reference/20129250 199. Csepanyi 2018: The Effects of Long-Term, Low- and High-Dose Beta-Carotene Treatment in Zucker Diabetic Fatty Rats: The Role of HO-1, Int. J. Mol. Sci., 19, p. 1132, DOI: 10.3390/ijms19041132 199 10.3390/ijms19041132 false true Reference 20129251 /api/reference/20129251 200. Feidantsis 2018: Treatment with crocin improves cardiac dysfunction by normalizing autophagy and inhibiting apoptosis in STZ-induced diabetic cardiomyopathy, Nutr. Metab. Cardiovasc. Dis., 28, p. 952, DOI: 10.1016/j.numecd.2018.06.005 200 10.1016/j.numecd.2018.06.005 false true Reference 20129252 /api/reference/20129252 201. Xu 2017: Bixin ameliorates high fat diet-induced cardiac injury in mice through inflammation and oxidative stress suppression, Biomed. Pharmacother., 89, p. 991, DOI: 10.1016/j.biopha.2017.02.052 201 10.1016/j.biopha.2017.02.052 false true Reference 20129253 /api/reference/20129253 202. Zhao 2020: Beta carotene protects H9c2 cardiomyocytes from advanced glycation end product-induced endoplasmic reticulum stress, apoptosis, and autophagy via the PI3K/Akt/mTOR signaling pathway, Ann. Transl. Med., 8, DOI: 10.21037/atm-20-3768 202 10.21037/atm-20-3768 false true Reference 20129254 /api/reference/20129254 203. Manolescu 2014: All- trans retinoic acid stimulates gene expression of the cardioprotective natriuretic peptide system and prevents fibrosis and apoptosis in cardiomyocytes of obese ob/ob mice, Appl. Physiol. Nutr. Metab., 39, p. 1127, DOI: 10.1139/apnm-2014-0005 203 10.1139/apnm-2014-0005 false true Reference 20129255 /api/reference/20129255 204. El-Fawal 2019: Effects of diosmin and crocin on metabolic syndrome-associated cardio-vascular complications in rats, Naunyn. Schmiedebergs. Arch. Pharmacol., 392, p. 1523, DOI: 10.1007/s00210-019-01700-8 204 10.1007/s00210-019-01700-8 false true Reference 20129256 /api/reference/20129256 205. Rohini 2018: Norbixin, an apocarotenoid derivative activates PPARγ in cardiometabolic syndrome: Validation by in silico and in vivo experimental assessment, Life Sci, 209, p. 69, DOI: 10.1016/j.lfs.2018.08.001 205 10.1016/j.lfs.2018.08.001 false true Reference 20129257 /api/reference/20129257 206. Zolberg Relevy 2015: The Inhibition of Macrophage Foam Cell Formation by 9-Cis β-Carotene Is Driven by BCMO1 Activity, PLoS One, 10, DOI: 10.1371/journal.pone.0115272 206 10.1371/journal.pone.0115272 false true Reference 20129258 /api/reference/20129258 207. Sharavana 2017: Lutein attenuates oxidative stress markers and ameliorates glucose homeostasis through polyol pathway in heart and kidney of STZ-induced hyperglycemic rat model, Eur. J. Nutr., 56, p. 2475, DOI: 10.1007/s00394-016-1283-0 207 10.1007/s00394-016-1283-0 false true Reference 20129259 /api/reference/20129259 208. Poudyal 2010: Comparison of purple carrot juice and β-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome, Br. J. Nutr., 104, p. 1322, DOI: 10.1017/S0007114510002308 208 10.1017/S0007114510002308 false true Reference 20129260 /api/reference/20129260 209. Karppi 2013: Serum Carotenoids Reduce Progression of Early Atherosclerosis in the Carotid Artery Wall among Eastern Finnish Men, PLoS One, 8, DOI: 10.1371/journal.pone.0064107 209 10.1371/journal.pone.0064107 false true Reference 20129261 /api/reference/20129261 210. Abedimanesh 2019: The effect of crocetin supplementation on markers of atherogenic risk in patients with coronary artery disease: a pilot, randomized, double-blind, placebo-controlled clinical trial, Food Funct, 10, p. 7461, DOI: 10.1039/C9FO01166H 210 10.1039/C9FO01166H false true Reference 20129262 /api/reference/20129262 211. Olsen 2018: The risk association of plasma total homocysteine with acute myocardial infarction is modified by serum vitamin A, Eur. J. Prev. Cardiol., 25, p. 1612, DOI: 10.1177/2047487318788587 211 10.1177/2047487318788587 false true Reference 20129263 /api/reference/20129263 212. Choi 2012: Independent association of serum retinol and β-carotene levels with hyperuricemia: A national population study, Arthritis Care Res. (Hoboken)., 64, p. 389, DOI: 10.1002/acr.20692 212 10.1002/acr.20692 false true Reference 20129264 /api/reference/20129264 213. Osipani 2017: Vitamins D and E combbined effect on the rat myocardium under alloxan-induced diabetes, Georg. Med News, p. 102 213 false true Reference 20129265 /api/reference/20129265 214. Tabei 2015: Effect of vitamins A, E, C and omega-3 fatty acids supplementation on the level of catalase and superoxide dismutase activities in streptozotocin-induced diabetic rats, Bratislava Med. J., 116, p. 115, DOI: 10.4149/BLL_2015_022 214 10.4149/BLL_2015_022 false true Reference 20129266 /api/reference/20129266 215. Joseph 2008: Effect of Anti-oxidant Treatment on Hyperhomocysteinemia-induced Myocardial Fibrosis and Diastolic Dysfunction, J. Hear. Lung Transplant., 27, p. 1237, DOI: 10.1016/j.healun.2008.07.024 215 10.1016/j.healun.2008.07.024 false true Reference 20129267 /api/reference/20129267 216. Yusuf 2000: Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients, N. Engl. J. Med., 342, p. 154, DOI: 10.1056/NEJM200001203420302 216 10.1056/NEJM200001203420302 false true Reference 20129268 /api/reference/20129268 217. Palumbo 2000: Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients, Am. J. Hypertens., 13, p. 564, DOI: 10.1016/S0895-7061(00)00244-2 217 10.1016/S0895-7061(00)00244-2 false true Reference 20129269 /api/reference/20129269 218. Kim 2002: Lack of Long-Term Effect of Vitamin C Supplementation on Blood Pressure, Hypertension, 40, p. 797, DOI: 10.1161/01.HYP.0000038339.67450.60 218 10.1161/01.HYP.0000038339.67450.60 false true Reference 20129270 /api/reference/20129270 219. Myung 2013: Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials, BMJ, 346, DOI: 10.1136/bmj.f10 219 10.1136/bmj.f10 false true Reference 20129271 /api/reference/20129271 220. Reiter 2016: Melatonin as an antioxidant: under promises but over delivers, J. Pineal Res., 61, p. 253, DOI: 10.1111/jpi.12360 220 10.1111/jpi.12360 false true Reference 20129272 /api/reference/20129272 221. Nduhirabandi 2010: Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity, J. Pineal Res., 50, p. 171 221 false true Reference 20129273 /api/reference/20129273 222. Nduhirabandi 2014: Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity, J. Pineal Res., 57, p. 317, DOI: 10.1111/jpi.12171 222 10.1111/jpi.12171 false true Reference 20129274 /api/reference/20129274 223. Diez 2013: Melatonin, given at the time of reperfusion, prevents ventricular arrhythmias in isolated hearts from fructose-fed rats and spontaneously hypertensive rats, J. Pineal Res., 55, p. 166, DOI: 10.1111/jpi.12059 223 10.1111/jpi.12059 false true Reference 20129275 /api/reference/20129275 224. Yu 2018: Melatonin protects diabetic heart against ischemia-reperfusion injury, role of membrane receptor-dependent cGMP-PKG activation, Biochim. Biophys. Acta - Mol. Basis Dis., 1864, p. 563, DOI: 10.1016/j.bbadis.2017.11.023 224 10.1016/j.bbadis.2017.11.023 false true Reference 20129276 /api/reference/20129276 225. Yu 2017: Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling, Sci. Rep., 7, p. 41337, DOI: 10.1038/srep41337 225 10.1038/srep41337 false true Reference 20129277 /api/reference/20129277 226. Yu 2021: Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia‐reperfusion injury by improving mitochondrial quality control: Role of SIRT6, J. Pineal Res., 70, DOI: 10.1111/jpi.12698 226 10.1111/jpi.12698 false true Reference 20129278 /api/reference/20129278 227. Dhanabalan 2020: Mitochondrial Oxidative Phosphorylation Function and Mitophagy in Ischaemic/Reperfused Hearts from Control and High-Fat Diet Rats: Effects of Long-Term Melatonin Treatment, Cardiovasc. Drugs Ther., 34, p. 799, DOI: 10.1007/s10557-020-06997-9 227 10.1007/s10557-020-06997-9 false true Reference 20129279 /api/reference/20129279 228. Dwaich 2016: Melatonin effects on myocardial ischemia–reperfusion injury: Impact on the outcome in patients undergoing coronary artery bypass grafting surgery, Int. J. Cardiol., 221, p. 977, DOI: 10.1016/j.ijcard.2016.07.108 228 10.1016/j.ijcard.2016.07.108 false true Reference 20129280 /api/reference/20129280 229. Dominguez-Rodriguez 2017: Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty trial, J. Pineal Res., 62, DOI: 10.1111/jpi.12374 229 10.1111/jpi.12374 false true Reference 20129281 /api/reference/20129281 230. Dominguez-Rodriguez 2017: Usefulness of Early Treatment With Melatonin to Reduce Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention (From the Melatonin Adjunct in the Acute Myocardial Infarction Treated With Angiop, Am. J. Cardiol., 120, p. 522, DOI: 10.1016/j.amjcard.2017.05.018 230 10.1016/j.amjcard.2017.05.018 false true Reference 20129282 /api/reference/20129282 231. Gülçin 2006: Antioxidant and antiradical activities of l-carnitine, Life Sci, 78, p. 803, DOI: 10.1016/j.lfs.2005.05.103 231 10.1016/j.lfs.2005.05.103 false true Reference 20129283 /api/reference/20129283 232. Wang 2013: Acetyl-l-Carnitine and Oxfenicine on Cardiac Pumping Mechanics in Streptozotocin-Induced Diabetes in Male Wistar Rats, PLoS One, 8 232 false true Reference 20129284 /api/reference/20129284 233. Strilakou 2013: Heart dysfunction induced by choline-deficiency in adult rats: The protective role of l-carnitine, Eur. J. Pharmacol., 709, p. 20, DOI: 10.1016/j.ejphar.2013.03.025 233 10.1016/j.ejphar.2013.03.025 false true Reference 20129285 /api/reference/20129285 234. Rodrigues 1990: Lack of effect of oral treatment on lipid metabolism and cardiac function in chronically diabetic rats, Can. J. Physiol. Pharmacol., 68, p. 1601, DOI: 10.1139/y90-244 234 10.1139/y90-244 false true Reference 20129286 /api/reference/20129286 235. Rodrigues 1988: Effect of L-Carnitine Treatment on Lipid Metabolism and Cardiac Performance in Chronically Diabetic Rats, Diabetes, 37, p. 1358, DOI: 10.2337/diab.37.10.1358 235 10.2337/diab.37.10.1358 false true Reference 20129287 /api/reference/20129287 236. Broderick 2008: ATP Production and TCA Activity are Stimulated by Propionyl-L-Carnitine in the Diabetic Rat Heart, Drugs R D, 9, p. 83, DOI: 10.2165/00126839-200809020-00003 236 10.2165/00126839-200809020-00003 false true Reference 20129288 /api/reference/20129288 237. Terada 1998: Effects of propionyl-l-carnitine on cardiac dysfunction in streptozotocin-diabetic rats, Eur. J. Pharmacol., 357, p. 185, DOI: 10.1016/S0014-2999(98)00539-1 237 10.1016/S0014-2999(98)00539-1 false true Reference 20129289 /api/reference/20129289 238. Broderick 2004: Effects of Propionyl-Carnitine on Mitochondrial Respiration and Post-Ischaemic Cardiac Function in the Ischaemic Underperfused Diabetic Rat Heart, Drugs R D, 5, p. 191, DOI: 10.2165/00126839-200405040-00002 238 10.2165/00126839-200405040-00002 false true Reference 20129290 /api/reference/20129290 239. Felix 2001: Effects of propionyl-l-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart, Diabetes Res. Clin. Pract., 53, p. 17, DOI: 10.1016/S0168-8227(01)00240-6 239 10.1016/S0168-8227(01)00240-6 false true Reference 20129291 /api/reference/20129291 240. Broderick 1996: L-propionylcarnitine Enhancement of Substrate Oxidation and Mitochondrial Respiration in the Diabetic Rat Heart, J. Mol. Cell. Cardiol., 28, p. 331, DOI: 10.1006/jmcc.1996.0031 240 10.1006/jmcc.1996.0031 false true Reference 20129292 /api/reference/20129292 241. Broderick 2000: Propionyl-L-carnitine effects on postischemic recovery of heart function and substrate oxidation in diabetic rat, Mol. Cell. Biochem., 206, p. 151, DOI: 10.1023/A:1007022114594 241 10.1023/A:1007022114594 false true Reference 20129293 /api/reference/20129293 242. Lango 2005: Propionyl-L-Carnitine Improves Hemodynamics and Metabolic Markers of Cardiac Perfusion during Coronary Surgery in Diabetic Patients, Cardiovasc. Drugs Ther., 19, p. 267, DOI: 10.1007/s10557-005-3349-8 242 10.1007/s10557-005-3349-8 false true Reference 20129294 /api/reference/20129294 243. Turpeinen 2000: Long-term effect of acetyl-L-carnitine on myocardial123I-MIBG uptake in patients with diabetes, Clin. Auton. Res., 10, p. 13, DOI: 10.1007/BF02291384 243 10.1007/BF02291384 false true Reference 20129295 /api/reference/20129295 244. Dambrova 2014: Risks and Benefits of Carnitine Supplementation in Diabetes, Exp. Clin. Endocrinol. Diabetes., 123, p. 95, DOI: 10.1055/s-0034-1390481 244 10.1055/s-0034-1390481 false true Reference 20129296 /api/reference/20129296 245. Jeong 2016: Downregulation of Reactive Oxygen Species in Apoptosis, J. Cancer Prev., 21, p. 13, DOI: 10.15430/JCP.2016.21.1.13 245 10.15430/JCP.2016.21.1.13 false true Reference 20129297 /api/reference/20129297 246. Rahman 2007: Studies on free radicals, antioxidants, and co-factors, Clin. Interv. Aging., 2, p. 219 246 false true Reference 20129298 /api/reference/20129298 247. Chatterjee 2013: Reduced Glutathione: A Radioprotector or a Modulator of DNA-Repair Activity?, Nutrients, 5, p. 525, DOI: 10.3390/nu5020525 247 10.3390/nu5020525 false true Reference 20129299 /api/reference/20129299 248. Ueno 2002: Dietary Glutathione Protects Rats from Diabetic Nephropathy and Neuropathy, J. Nutr., 132, p. 897, DOI: 10.1093/jn/132.5.897 248 10.1093/jn/132.5.897 false true Reference 20129300 /api/reference/20129300 249. Sekhar 2011: Glutathione Synthesis Is Diminished in Patients With Uncontrolled Diabetes and Restored by Dietary Supplementation With Cysteine and Glycine, Diabetes Care, 34, p. 162, DOI: 10.2337/dc10-1006 249 10.2337/dc10-1006 false true Reference 20129301 /api/reference/20129301 250. Singh 2007: Coenzyme Q10 Supplementation and Heart Failure, Nutr. Rev., 65, p. 286, DOI: 10.1111/j.1753-4887.2007.tb00306.x 250 10.1111/j.1753-4887.2007.tb00306.x false true Reference 20129302 /api/reference/20129302 251. Quijano 2007: Enhanced mitochondrial superoxide in hyperglycemic endothelial cells: direct measurements and formation of hydrogen peroxide and peroxynitrite, Am. J. Physiol. Circ. Physiol., 293, p. H3404, DOI: 10.1152/ajpheart.00761.2007 251 10.1152/ajpheart.00761.2007 false true Reference 20129303 /api/reference/20129303 252. Mercer 2012: The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/–/ApoE–/– mice, Free Radic. Biol. Med., 52, p. 841, DOI: 10.1016/j.freeradbiomed.2011.11.026 252 10.1016/j.freeradbiomed.2011.11.026 false true Reference 20129304 /api/reference/20129304 253. Zozina 2018: Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem, Curr. Cardiol. Rev., 14, p. 164, DOI: 10.2174/1573403X14666180416115428 253 10.2174/1573403X14666180416115428 false true Reference 20129305 /api/reference/20129305 254. Oettl 2002: Pteridine Derivatives as Modulators of Oxidative Stress, Curr. Drug Metab., 3, p. 203, DOI: 10.2174/1389200024605127 254 10.2174/1389200024605127 false true Reference 20129306 /api/reference/20129306 255. Baumgardt 2016: Chronic Co-Administration of Sepiapterin and &lt;scp&gt;l&lt;/scp&gt; -Citrulline Ameliorates Diabetic Cardiomyopathy and Myocardial Ischemia/Reperfusion Injury in Obese Type 2 Diabetic Mice, Circ. Hear. Fail., 9 255 false true Reference 20129307 /api/reference/20129307 256. Okazaki 2011: Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart, J. Mol. Cell. Cardiol., 50, p. 534, DOI: 10.1016/j.yjmcc.2010.12.010 256 10.1016/j.yjmcc.2010.12.010 false true Reference 20129308 /api/reference/20129308 257. Kim 2020: BH4 activates CaMKK2 and rescues the cardiomyopathic phenotype in rodent models of diabetes, Life Sci. Alliance., 3, DOI: 10.26508/lsa.201900619 257 10.26508/lsa.201900619 false true Reference 20129309 /api/reference/20129309 258. Settergren 2009: l-Arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease, Atherosclerosis, 204, p. 73, DOI: 10.1016/j.atherosclerosis.2008.08.034 258 10.1016/j.atherosclerosis.2008.08.034 false true Reference 20129310 /api/reference/20129310 259. Kaye 2020: Folic Acid Supplementation in Patients with Elevated Homocysteine Levels, Adv. Ther., 37, p. 4149, DOI: 10.1007/s12325-020-01474-z 259 10.1007/s12325-020-01474-z false true Reference 20129311 /api/reference/20129311 260. Joshi 2001: Free radical scavenging behavior of folic acid: evidence for possible antioxidant activity, Free Radic. Biol. Med., 30, p. 1390, DOI: 10.1016/S0891-5849(01)00543-3 260 10.1016/S0891-5849(01)00543-3 false true Reference 20129312 /api/reference/20129312 261. Stroes 2000: Folic Acid Reverts Dysfunction of Endothelial Nitric Oxide Synthase, Circ. Res., 86, p. 1129, DOI: 10.1161/01.RES.86.11.1129 261 10.1161/01.RES.86.11.1129 false true Reference 20129313 /api/reference/20129313 262. Chalupsky 2015: Folic Acid Promotes Recycling of Tetrahydrobiopterin and Protects Against Hypoxia-Induced Pulmonary Hypertension by Recoupling Endothelial Nitric Oxide Synthase, Antioxid. Redox Signal., 23, p. 1076, DOI: 10.1089/ars.2015.6329 262 10.1089/ars.2015.6329 false true Reference 20129314 /api/reference/20129314 263. Mutavdzin 2019: The Effects of Folic Acid Administration on Cardiac Oxidative Stress and Cardiovascular Biomarkers in Diabetic Rats, Oxid. Med. Cell. Longev., p. 1, DOI: 10.1155/2019/1342549 263 10.1155/2019/1342549 false true Reference 20129315 /api/reference/20129315 264. Wu 2008: Effects of Folic Acid on Cardiac Myocyte Apoptosis in Rats with Streptozotocin-induced Diabetes Mellitus, Cardiovasc. Drugs Ther., 22, p. 299, DOI: 10.1007/s10557-008-6109-8 264 10.1007/s10557-008-6109-8 false true Reference 20129316 /api/reference/20129316 265. Kolling 2011: Homocysteine Induces Oxidative–Nitrative Stress in Heart of Rats: Prevention by Folic Acid, Cardiovasc. Toxicol., 11, p. 67, DOI: 10.1007/s12012-010-9094-7 265 10.1007/s12012-010-9094-7 false true Reference 20129317 /api/reference/20129317 266. Zuurbier 2014: Cardioprotective efficacy depends critically on pharmacological dose, duration of ischaemia, health status of animals and choice of anaesthetic regimen: a case study with folic acid, J. Transl. Med., 12, p. 325, DOI: 10.1186/s12967-014-0325-8 266 10.1186/s12967-014-0325-8 false true Reference 20129318 /api/reference/20129318 267. Petersen Shay 2008: Is α-lipoic acid a scavenger of reactive oxygen speciesin vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity, IUBMB Life, 60, p. 362, DOI: 10.1002/iub.40 267 10.1002/iub.40 false true Reference 20129319 /api/reference/20129319 268. Dworacka 2018: New arguments for beneficial effects of alpha-lipoic acid on the cardiovascular system in the course of type 2 diabetes, Eur. J. Pharm. Sci., 117, p. 41, DOI: 10.1016/j.ejps.2018.02.009 268 10.1016/j.ejps.2018.02.009 false true Reference 20129320 /api/reference/20129320 269. Li 2012: Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid, Cardiovasc. Diabetol., 11, p. 73, DOI: 10.1186/1475-2840-11-73 269 10.1186/1475-2840-11-73 false true Reference 20129321 /api/reference/20129321 270. Pop 2020: Protective Effects of a Discontinuous Treatment with Alpha-Lipoic Acid in Obesity-Related Heart Failure with Preserved Ejection Fraction, in Rats, Antioxidants, 9, p. 1073, DOI: 10.3390/antiox9111073 270 10.3390/antiox9111073 false true Reference 20129322 /api/reference/20129322 271. Broskova 2013: Ischemia-reperfusion injury of the isolated diabetic rat heart: effect of the antioxidant stobadine, Gen. Physiol. Biophys., 32, p. 285, DOI: 10.4149/gpb_2013028 271 10.4149/gpb_2013028 false true Reference 20129323 /api/reference/20129323 272. AL-Rasheed 2013: Adverse cardiac responses to alpha-lipoic acid in a rat-diabetic model: possible mechanisms?, J. Physiol. Biochem., 69, p. 761, DOI: 10.1007/s13105-013-0252-9 272 10.1007/s13105-013-0252-9 false true Reference 20129324 /api/reference/20129324 273. Çakatay 2006: Pro-oxidant actions of α-lipoic acid and dihydrolipoic acid, Med. Hypotheses., 66, p. 110, DOI: 10.1016/j.mehy.2005.07.020 273 10.1016/j.mehy.2005.07.020 false true Reference 20129325 /api/reference/20129325 274. McIlduff 2011: Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy, Ther. Clin. Risk Manag., 7, p. 377 274 false true Reference 20129326 /api/reference/20129326 275. Tromba 2019: Effect of Alpha-Lipoic Acid Supplementation on Endothelial Function and Cardiovascular Risk Factors in Overweight/Obese Youths: A Double-Blind, Placebo-Controlled Randomized Trial, Nutrients, 11, p. 375, DOI: 10.3390/nu11020375 275 10.3390/nu11020375 false true Reference 20129327 /api/reference/20129327 276. Huang 2008: The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus, Pediatr. Diabetes., 9, p. 69, DOI: 10.1111/j.1399-5448.2007.00342.x 276 10.1111/j.1399-5448.2007.00342.x false true Reference 20129328 /api/reference/20129328 277. Altunina 2020: Alpha-Lipoic Acid as a Means of Influence on Systemic Inflammation in Type 2 Diabetes Mellitus Patients with Prior Myocardial Infarction, J. Med. Life., 13, p. 32 277 false true Reference 20129329 /api/reference/20129329 278. Hegazy 2013: Alpha-Lipoic Acid Improves Subclinical Left Ventricular Dysfunction in Asymptomatic Patients with Type 1 Diabetes, Rev. Diabet. Stud., 10, p. 58, DOI: 10.1900/RDS.2013.10.58 278 10.1900/RDS.2013.10.58 false true Reference 20129330 /api/reference/20129330 279. Dayanandan 2001: Protective role of L-carnitine on liver and heart lipid peroxidation in atherosclerotic rats, J. Nutr. Biochem., 12, p. 254, DOI: 10.1016/S0955-2863(00)00151-0 279 10.1016/S0955-2863(00)00151-0 false true Reference 20129331 /api/reference/20129331 280. Broderick 1995: L-carnitine increases glucose metabolism and mechanical function following ischaemia in diabetic rat heart, Cardiovasc. Res., 29, p. 373, DOI: 10.1016/0008-6363(96)88594-4 280 10.1016/0008-6363(96)88594-4 false true Reference 20129332 /api/reference/20129332 281. Paulson 1992: Protection of the ischemic diabetic heart by L-propionylcarnitine therapy, Mol. Cell. Biochem., 116, p. 131, DOI: 10.1007/BF01270580 281 10.1007/BF01270580 false true Reference 20129333 /api/reference/20129333 282. Bartekova 2018: Beneficial Effects of N-acetylcysteine and N-mercaptopropionylglycine on Ischemia Reperfusion Injury in the Heart, Curr. Med. Chem., 25, p. 355, DOI: 10.2174/0929867324666170608111917 282 10.2174/0929867324666170608111917 false true Reference 20129334 /api/reference/20129334 283. Su 2016: N-acetylcysteine attenuates myocardial dysfunction and postischemic injury by restoring caveolin-3/eNOS signaling in diabetic rats, Cardiovasc. Diabetol., 15, p. 146, DOI: 10.1186/s12933-016-0460-z 283 10.1186/s12933-016-0460-z false true Reference 20129335 /api/reference/20129335 284. Li 2020: Mechanism of N-acetylcysteine in alleviating diabetic myocardial ischemia reperfusion injury by regulating PTEN/Akt pathway through promoting DJ-1, Biosci. Rep., 40 284 false true Reference 20129336 /api/reference/20129336 285. Suzuki 2015: Arachidonate 12/15-Lipoxygenase–Induced Inflammation and Oxidative Stress Are Involved in the Development of Diabetic Cardiomyopathy, Diabetes, 64, p. 618, DOI: 10.2337/db13-1896 285 10.2337/db13-1896 false true Reference 20129337 /api/reference/20129337 286. Liu 2015: N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition, BMC Cardiovasc. Disord., 15, p. 84, DOI: 10.1186/s12872-015-0076-3 286 10.1186/s12872-015-0076-3 false true Reference 20129338 /api/reference/20129338 287. He 2018: Palmitic acid, but not high-glucose, induced myocardial apoptosis is alleviated by N-acetylcysteine due to attenuated mitochondrial-derived ROS accumulation-induced endoplasmic reticulum stress, Cell Death Dis, 9, p. 568, DOI: 10.1038/s41419-018-0593-y 287 10.1038/s41419-018-0593-y false true Reference 20129339 /api/reference/20129339 288. Wang 2020: Engineered cardiac tissues: a novel in vitro model to investigate the pathophysiology of mouse diabetic cardiomyopathy, Acta Pharmacol. Sin., DOI: 10.1038/s41401-020-00538-8 288 10.1038/s41401-020-00538-8 false true Reference 20129340 /api/reference/20129340 289. Yildirim 2013: Relationship Between Downregulation of miRNAs and Increase of Oxidative Stress in the Development of Diabetic Cardiac Dysfunction: Junctin as a Target Protein of miR-1, Cell Biochem. Biophys., 67, p. 1397, DOI: 10.1007/s12013-013-9672-y 289 10.1007/s12013-013-9672-y false true Reference 20129341 /api/reference/20129341 290. Li 2018: High Uric Acid Inhibits Cardiomyocyte Viability Through the ERK/P38 Pathway via Oxidative Stress, Cell. Physiol. Biochem., 45, p. 1156, DOI: 10.1159/000487356 290 10.1159/000487356 false true Reference 20129342 /api/reference/20129342 291. Balderas-Villalobos 2013: Oxidative stress in cardiomyocytes contributes to decreased SERCA2a activity in rats with metabolic syndrome, Am. J. Physiol. Circ. Physiol., 305, p. H1344, DOI: 10.1152/ajpheart.00211.2013 291 10.1152/ajpheart.00211.2013 false true Reference 20129343 /api/reference/20129343 292. Lin 2004: Effect of five cysteine-containing compounds on three lipogenic enzymes in Balb/cA mice consuming a high saturated fat diet, Lipids, 39, p. 843, DOI: 10.1007/s11745-004-1305-4 292 10.1007/s11745-004-1305-4 false true Reference 20129344 /api/reference/20129344 293. Maharani 2015: Molecular Mechanisms Underlying Urate-Induced Enhancement of Kv1.5 Channel Expression in HL-1 Atrial Myocytes, Circ. J., 79, p. 2659, DOI: 10.1253/circj.CJ-15-0416 293 10.1253/circj.CJ-15-0416 false true Reference 20129345 /api/reference/20129345 294. Kostić 2019: The effects of l-cysteine and N-acetyl-l-cysteine on homocysteine metabolism and haemostatic markers, and on cardiac and aortic histology in subchronically methionine-treated Wistar male rats, Mol. Cell. Biochem., 451, p. 43, DOI: 10.1007/s11010-018-3391-z 294 10.1007/s11010-018-3391-z false true Reference 20129346 /api/reference/20129346 295. Orhan 2006: Effects of N-acetylcysteine on myocardial ischemia–reperfusion injury in bypass surgery, Heart Vessels, 21, p. 42, DOI: 10.1007/s00380-005-0873-1 295 10.1007/s00380-005-0873-1 false true Reference 20129347 /api/reference/20129347 296. O. Peker, T. Peker, D. Erdogan, M. Ozaydin, S. Kapan, R. Sutcu, E. Ibrisim, Effects of intravenous N-acetylcysteine on periprocedural myocardial injury after on-pump coronary artery by-pass grafting, 2008. 4 (49AD). 296 false true Reference 20129348 /api/reference/20129348 297. Thiele 2010: Impact of High-Dose N-Acetylcysteine Versus Placebo on Contrast-Induced Nephropathy and Myocardial Reperfusion Injury in Unselected Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention, J. Am. Coll. Cardiol., 55, p. 2201, DOI: 10.1016/j.jacc.2009.08.091 297 10.1016/j.jacc.2009.08.091 false true Reference 20129349 /api/reference/20129349 298. Kinscherf 2003: Cholesterol levels linked to abnormal plasma thiol concentrations and thiol/disulfide redox status in hyperlipidemic subjects, Free Radic. Biol. Med., 35, p. 1286, DOI: 10.1016/j.freeradbiomed.2003.07.001 298 10.1016/j.freeradbiomed.2003.07.001 false true Reference 20129350 /api/reference/20129350 299. Yilmaz 2007: Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease, Acta Cardiol, 62, p. 579, DOI: 10.2143/AC.62.6.2024017 299 10.2143/AC.62.6.2024017 false true Reference 20129351 /api/reference/20129351 300. Miner 2002: N-acetylcysteine neither lowers plasma homocysteine concentrations nor improves brachial artery endothelial function in cardiac transplant recipients, Can. J. Cardiol., 18, p. 503 300 false true Reference 20129352 /api/reference/20129352 301. Mishra 2010: Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol, Cardiovasc. Diabetol., 9, p. 49, DOI: 10.1186/1475-2840-9-49 301 10.1186/1475-2840-9-49 false true Reference 20129353 /api/reference/20129353 302. Fukuda 2010: Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice, J. Hypertens., 28, p. 340, DOI: 10.1097/HJH.0b013e32833366cd 302 10.1097/HJH.0b013e32833366cd false true Reference 20129354 /api/reference/20129354 303. Federico 2017: Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance, J. Physiol., 595, p. 4089, DOI: 10.1113/JP273714 303 10.1113/JP273714 false true Reference 20129355 /api/reference/20129355 304. Cannizzo 2014: Tempol attenuates atherosclerosis associated with metabolic syndrome via decreased vascular inflammation and NADPH-2 oxidase expression, Free Radic. Res., 48, p. 526, DOI: 10.3109/10715762.2014.889295 304 10.3109/10715762.2014.889295 false true Reference 20129356 /api/reference/20129356 305. Wilcox 2010: Effects of tempol and redox-cycling nitroxides in models of oxidative stress, Pharmacol. Ther., 126, p. 119, DOI: 10.1016/j.pharmthera.2010.01.003 305 10.1016/j.pharmthera.2010.01.003 false true Reference 20129357 /api/reference/20129357 306. Taye 2013: Tempol ameliorates cardiac fibrosis in streptozotocin-induced diabetic rats: role of oxidative stress in diabetic cardiomyopathy, Naunyn. Schmiedebergs. Arch. Pharmacol., 386, p. 1071, DOI: 10.1007/s00210-013-0904-x 306 10.1007/s00210-013-0904-x false true Reference 20129358 /api/reference/20129358 307. Jagadeesha 2005: Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats, Am. J. Physiol. Circ. Physiol., 289, p. H1047, DOI: 10.1152/ajpheart.01071.2004 307 10.1152/ajpheart.01071.2004 false true Reference 20129359 /api/reference/20129359 308. Suematsu 2007: Hyperhomocysteinemia Alters Cardiac Substrate Metabolism by Impairing Nitric Oxide Bioavailability Through Oxidative Stress, Circulation, 115, p. 255, DOI: 10.1161/CIRCULATIONAHA.106.652693 308 10.1161/CIRCULATIONAHA.106.652693 false true Reference 20129360 /api/reference/20129360 309. Chen 2011: Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia, Am. J. Physiol. Circ. Physiol., 301, p. H1107, DOI: 10.1152/ajpheart.01071.2010 309 10.1152/ajpheart.01071.2010 false true Reference 20129361 /api/reference/20129361 310. Ni 2016: Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy, Free Radic. Biol. Med., 90, p. 12, DOI: 10.1016/j.freeradbiomed.2015.11.013 310 10.1016/j.freeradbiomed.2015.11.013 false true Reference 20129362 /api/reference/20129362 311. Liu 2017: The opposite effects of nitric oxide donor, S-nitrosoglutathione, on myocardial ischaemia/reperfusion injury in diabetic and non-diabetic mice, Clin. Exp. Pharmacol. Physiol., 44, p. 854, DOI: 10.1111/1440-1681.12781 311 10.1111/1440-1681.12781 false true Reference 20129363 /api/reference/20129363 312. Liu 2012: The alternative crosstalk between RAGE and nitrative thioredoxin inactivation during diabetic myocardial ischemia-reperfusion injury, Am. J. Physiol. Metab., 303, p. E841 312 false true Reference 20129364 /api/reference/20129364 313. Yin 2010: Nitrative inactivation of thioredoxin-1 increases vulnerability of diabetic hearts to ischemia/reperfusion injury, J. Mol. Cell. Cardiol., 49, p. 354, DOI: 10.1016/j.yjmcc.2010.05.002 313 10.1016/j.yjmcc.2010.05.002 false true Reference 20129365 /api/reference/20129365 314. Yamashita 2009: Where are we with probucol: A new life for an old drug?, Atherosclerosis, 207, p. 16, DOI: 10.1016/j.atherosclerosis.2009.04.002 314 10.1016/j.atherosclerosis.2009.04.002 false true Reference 20129366 /api/reference/20129366 315. Tada 1992: Effects of Probucol on Impaired Cardiac Performance and Lipid Metabolism in Streptozotocin-Induced Diabetic Rats, J. Cardiovasc. Pharmacol., 20, p. 179, DOI: 10.1097/00005344-199208000-00002 315 10.1097/00005344-199208000-00002 false true Reference 20129367 /api/reference/20129367 316. Nishio 1998: Altered Activities of Transcription Factors and Their Related Gene Expression in Cardiac Tissues of Diabetic Rats, Diabetes, 47, p. 1318, DOI: 10.2337/diab.47.8.1318 316 10.2337/diab.47.8.1318 false true Reference 20129368 /api/reference/20129368 317. Braun 2003: Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse, Proc. Natl. Acad. Sci., 100, p. 7283, DOI: 10.1073/pnas.1237725100 317 10.1073/pnas.1237725100 false true Reference 20129369 /api/reference/20129369 318. Liu 2018: Effects of probucol on atherosclerotic plaque and soluble thrombomodulin in patients with coronary heart disease, Exp. Ther. Med., 16, p. 886 318 false true Reference 20129370 /api/reference/20129370 319. Yamashita 2021: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE), J. Atheroscler. Thromb., 28, p. 103, DOI: 10.5551/jat.55327 319 10.5551/jat.55327 false true Reference 20129371 /api/reference/20129371 320. Kang 2021: Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study, J. Atheroscler. Thromb., 28, p. 124, DOI: 10.5551/jat.55616 320 10.5551/jat.55616 false true Reference 20129372 /api/reference/20129372 321. Khong 2011: 3′,4′-Dihydroxyflavonol Antioxidant Attenuates Diastolic Dysfunction and Cardiac Remodeling in Streptozotocin-Induced Diabetic m(Ren2)27 Rats, PLoS One, 6, DOI: 10.1371/journal.pone.0022777 321 10.1371/journal.pone.0022777 false true Reference 20129373 /api/reference/20129373 322. Zhang 2016: High fructose causes cardiac hypertrophy via mitochondrial signaling pathway, Am J Transl Res, 8, p. 4869 322 false true Reference 20129374 /api/reference/20129374 323. Agarkov 2019: Influence of 10-(6-plastoquinonyl) decyltriphenylphosphonium on free-radical homeostasis in the heart and blood serum of rats with streptozotocin-induced hyperglycemia, World J. Diabetes., 10, p. 546, DOI: 10.4239/wjd.v10.i12.546 323 10.4239/wjd.v10.i12.546 false true Reference 20129375 /api/reference/20129375 324. Chandran 2009: Doxorubicin Inactivates Myocardial Cytochrome c Oxidase in Rats: Cardioprotection by Mito-Q, Biophys. J., 96, p. 1388, DOI: 10.1016/j.bpj.2008.10.042 324 10.1016/j.bpj.2008.10.042 false true Reference 20129376 /api/reference/20129376 325. Kurutas 2015: The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state, Nutr. J., 15, p. 71, DOI: 10.1186/s12937-016-0186-5 325 10.1186/s12937-016-0186-5 false true Reference 20129377 /api/reference/20129377 326. Li 2001: Gene Therapy With Extracellular Superoxide Dismutase Protects Conscious Rabbits Against Myocardial Infarction, Circulation, 103, p. 1893, DOI: 10.1161/01.CIR.103.14.1893 326 10.1161/01.CIR.103.14.1893 false true Reference 20129378 /api/reference/20129378 327. Lin 2019: Inhibition of Neointima Hyperplasia, Inflammation, and Reactive Oxygen Species in Balloon-Injured Arteries by HVJ Envelope Vector-Mediated Delivery of Superoxide Dismutase Gene, Transl, Stroke Res, 10, p. 413, DOI: 10.1007/s12975-018-0660-9 327 10.1007/s12975-018-0660-9 false true Reference 20129379 /api/reference/20129379 328. Bräsen 2007: Extracellular Superoxide Dismutase Accelerates Endothelial Recovery and Inhibits In-Stent Restenosis in Stented Atherosclerotic Watanabe Heritable Hyperlipidemic Rabbit Aorta, J. Am. Coll. Cardiol., 50, p. 2249, DOI: 10.1016/j.jacc.2007.08.038 328 10.1016/j.jacc.2007.08.038 false true Reference 20129380 /api/reference/20129380 329. FRANCIS 2001: Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?, Physiol. Genomics., 7, p. 79, DOI: 10.1152/physiolgenomics.00073.2001 329 10.1152/physiolgenomics.00073.2001 false true Reference 20129381 /api/reference/20129381 330. Pachori 2006: Chronic Recurrent Myocardial Ischemic Injury Is Significantly Attenuated by Pre-Emptive Adeno-Associated Virus Heme Oxygenase-1 Gene Delivery, J. Am. Coll. Cardiol., 47, p. 635, DOI: 10.1016/j.jacc.2005.09.038 330 10.1016/j.jacc.2005.09.038 false true Reference 20129382 /api/reference/20129382 331. Liu 2007: Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction, Am. J. Physiol. Circ. Physiol., 293, p. H48, DOI: 10.1152/ajpheart.00741.2006 331 10.1152/ajpheart.00741.2006 false true Reference 20129383 /api/reference/20129383 332. Juan 2001: Adenovirus-Mediated Heme Oxygenase-1 Gene Transfer Inhibits the Development of Atherosclerosis in Apolipoprotein E–Deficient Mice, Circulation, 104, p. 1519, DOI: 10.1161/hc3801.095663 332 10.1161/hc3801.095663 false true Reference 20129384 /api/reference/20129384 333. Liang 2019: MiR-451 antagonist protects against cardiac fibrosis in streptozotocin-induced diabetic mouse heart, Life Sci, 224, p. 12, DOI: 10.1016/j.lfs.2019.02.059 333 10.1016/j.lfs.2019.02.059 false true Reference 20129385 /api/reference/20129385 334. Yu 2015: Inhibiting microRNA-144 abates oxidative stress and reduces apoptosis in hearts of streptozotocin-induced diabetic mice, Cardiovasc. Pathol., 24, p. 375, DOI: 10.1016/j.carpath.2015.06.003 334 10.1016/j.carpath.2015.06.003 false true Reference 20129386 /api/reference/20129386 335. Tang 2018: Overexpression of miR-22 attenuates oxidative stress injury in diabetic cardiomyopathy via Sirt 1, Cardiovasc. Ther., 36, DOI: 10.1111/1755-5922.12318 335 10.1111/1755-5922.12318 false true Reference 20129387 /api/reference/20129387 336. Zheng 2015: Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice, Diabetologia, 58, p. 1949, DOI: 10.1007/s00125-015-3622-8 336 10.1007/s00125-015-3622-8 false true Reference 20129388 /api/reference/20129388 337. Schmidt 2015: Antioxidants in Translational Medicine, Antioxid. Redox Signal., 23, p. 1130, DOI: 10.1089/ars.2015.6393 337 10.1089/ars.2015.6393 false true Reference 20129389 /api/reference/20129389 338. Malishevskaia IV 2013: Therapeutic efficacy of quercetin in patients with is ischemic heart disease with underlying metabolic syndrome, Georg. Med News, p. 67 338 false true Reference 20129390 /api/reference/20129390 339. Shatylo 2021: Cardio-metabolic benefits of quercetin in elderly patients with metabolic syndrome, PharmaNutrition, 15, DOI: 10.1016/j.phanu.2020.100250 339 10.1016/j.phanu.2020.100250 false true Reference 20129391 /api/reference/20129391 340. Perrino 2017: Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart, Cardiovasc. Res., 113, p. 725, DOI: 10.1093/cvr/cvx070 340 10.1093/cvr/cvx070 false true Reference 20129392 /api/reference/20129392 341. Parini 2020: The Network Medicine Imperative and the Need for an International Network Medicine Consortium, Am. J. Med., 133, p. e451, DOI: 10.1016/j.amjmed.2020.03.034 341 10.1016/j.amjmed.2020.03.034 false true Reference 20129393 /api/reference/20129393 342. Levine 2011: Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic Discoveries, Adv. Nutr., 2, p. 78, DOI: 10.3945/an.110.000109 342 10.3945/an.110.000109 false true Reference 20129394 /api/reference/20129394 343. Ohara 2014: Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles, Curr. Drug Metab., 15, p. 37, DOI: 10.2174/1389200214666131210143407 343 10.2174/1389200214666131210143407 false true Reference 20129395 /api/reference/20129395 344. Pechanova 2020: Therapeutic Potential of Polyphenols-Loaded Polymeric Nanoparticles in Cardiovascular System, Molecules, 25, p. 3322, DOI: 10.3390/molecules25153322 344 10.3390/molecules25153322 false true Reference 20129396 /api/reference/20129396 345. El-Naggar 2019: Curcumin-loaded PLA-PEG copolymer nanoparticles for treatment of liver inflammation in streptozotocin-induced diabetic rats, Colloids Surfaces B Biointerfaces, 177, p. 389, DOI: 10.1016/j.colsurfb.2019.02.024 345 10.1016/j.colsurfb.2019.02.024 false true Reference 20129397 /api/reference/20129397 346. Ray 2016: Improved bioavailability of targeted Curcumin delivery efficiently regressed cardiac hypertrophy by modulating apoptotic load within cardiac microenvironment, Toxicol. Appl. Pharmacol., 290, p. 54, DOI: 10.1016/j.taap.2015.11.011 346 10.1016/j.taap.2015.11.011 false true Reference 20129398 /api/reference/20129398 347. Andreadou 2020: Hyperlipidaemia and cardioprotection: Animal models for translational studies, Br. J. Pharmacol., 177, p. 5287, DOI: 10.1111/bph.14931 347 10.1111/bph.14931 false true Reference 20129399 /api/reference/20129399 348. Renner 2020: Porcine models for studying complications and organ crosstalk in diabetes mellitus, Cell Tissue Res, 380, p. 341, DOI: 10.1007/s00441-019-03158-9 348 10.1007/s00441-019-03158-9 false true Reference 20129400 /api/reference/20129400 349. Mangge 2014: Antioxidants, inflammation and cardiovascular disease, World J. Cardiol., 6, p. 462, DOI: 10.4330/wjc.v6.i6.462 349 10.4330/wjc.v6.i6.462 false true Reference 20129401 /api/reference/20129401 350. Savoji 2019: Cardiovascular disease models: A game changing paradigm in drug discovery and screening, Biomaterials, 198, p. 3, DOI: 10.1016/j.biomaterials.2018.09.036 350 10.1016/j.biomaterials.2018.09.036 false true /api/publication/31991804 Barteková Monika et al. Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases. (2021) FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 1873-4596 169 446-477<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Barteková Monika ✉ </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Adameová Adriana </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10027602"><a href="/gui2/?type=authors&mode=browse&sel=10027602" target="_blank">Görbe Anikó (<span class="authorship-author-name">Görbe Anikó</span> <span class="authorAux-mtmt"> orvostudomany</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Ferenczyová Kristína </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Pecháňová Oľga </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Lazou Antigone </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Dhalla Naranjan S. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10010125"><a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy Péter (<span class="authorship-author-name">Ferdinandy Péter</span> <span class="authorAux-mtmt"> Farmakológia, molekuláris medicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026898"><a href="/gui2/?type=authors&mode=browse&sel=10026898" target="_blank">Giricz Zoltán ✉ (<span class="authorship-author-name">Giricz Zoltán</span> <span class="authorAux-mtmt"> Biokémia, Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;31991804" target="_blank">Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases</a></div> <div> <span class="journal-title">FREE RADICAL BIOLOGY AND MEDICINE</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0891-5849">0891-5849</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1873-4596">1873-4596</a>)</span>: <span class="journal-volume">169</span> <span class="page"> pp 446-477 </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.freeradbiomed.2021.03.045" target="_blank" href="https://doi.org/10.1016/j.freeradbiomed.2021.03.045"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000653022000003" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000653022000003"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85105314704" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85105314704"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="33905865" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33905865&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Physiology (medical)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 99</span> | Független: 82 | Függő: 17 | Nem jelölt: 0 | WoS jelölt: 78 | Scopus jelölt:&nbsp;94 | WoS/Scopus jelölt:&nbsp;95 | DOI jelölt:&nbsp;93 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;31991804&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 20 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 31991804</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (NVKP_16-1-20160017) Támogató: OTKA, (Higher Education Institutional Excellence Programme of the Ministry of Human Capacities of Hungary, within the framework of the Therapeutic Development thematic programme of the Semmelweis University), (TKP/ITM/NKFIH), (ÚNKP-19-4) </div> <div class="lastModified">Utolsó módosítás: 2024.09.17. 09:53 Kovács Marcell (MTMT Közp., admin) </div> <div class="lockedBy">Központi kezelésű 2024.09.09. 09:21 Kovács Marcell (MTMT Közp., admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of SciencesBratislava 84104, Slovakia Institute of Physiology, Faculty of Medicine, Comenius University in BratislavaBratislava 81372, Slovakia Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in BratislavaBratislava 83232, Slovakia ...</pre> </div></div>